

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Information given by websites selling home self-sampling COVID-19 tests: An analysis of accuracy and completeness

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-042453
Article Type:	Original research
Date Submitted by the Author:	06-Jul-2020
Complete List of Authors:	<p>Taylor-Phillips, Sian; University of Warwick, Warwick Medical School          Berhane, Sarah; University of Birmingham, Institute of Applied Health Research          Sitch, Alice; University of Birmingham, Public Health, Epidemiology and Biostatistics          Freeman, Karoline; University of Warwick, Division of Health Sciences, Warwick Medical School          Price, Malcolm; University of Birmingham, Institute of Applied Health Research          Davenport, Clare; University of Birmingham, Epidemiology ,Public Health and Biostatistics          Geppert, Julia; University of Warwick, Warwick Medical School          Harris, Isobel; University of Birmingham          Osokogu, Osemeke; University of Warwick, Warwick Medical School          Skrybant, Magdalena; University of Birmingham          Deeks, Jonathan; University of Birmingham, Institute of Applied Health Research</p>
Keywords:	Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Public health < INFECTIOUS DISEASES, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Information given by websites selling home self-sampling COVID-19 tests: An analysis of accuracy**  
4 **and completeness**  
5

6 Taylor-Phillips S (0000-0002-1841-4346), Berhane S (0000-0002-1437-0411), Sitch AJ (0000-0001-  
7 7727-4497), Freeman K (0000-0002-9963-2918), Price MJ (0000-0002-7352-3027), Davenport C  
8 (0000-0001-5659-4889), Geppert J (0000-0001-6446-6094), Harris IM (0000-0001-8125-3832),  
9 Osokogu O, Skrybant M (0000-0001-7119-2482), Deeks JJ (0000-0002-8850-1971)

10  
11 Taylor-Phillips S, Professor of Population Health, Test Evaluation Research Group, Institute of Applied Health  
12 Research, University of Birmingham, Birmingham, UK and Warwick Medical School, University of Warwick,  
13 Coventry, UK

14  
15 Berhane S, Medical Statistician, Test Evaluation Research Group, Test Evaluation Research Group, Institute of  
16 Applied Health Research, University of Birmingham, Birmingham, UK and NIHR Birmingham Biomedical  
17 Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham,  
18 Birmingham, UK

19  
20 Sitch AJ, Senior Lecturer in Biostatistics, Test Evaluation Research Group, Institute of Applied Health Research,  
21 University of Birmingham, Birmingham, UK and NIHR Birmingham Biomedical Research Centre, University  
22 Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK

23  
24 Freeman K, Research Fellow, Institute of Applied Health Research, University of Birmingham, Birmingham, UK,  
25 and Warwick Medical School, University of Warwick, Coventry, UK

26  
27 Price MJ, Lecturer in Biostatistics, Test Evaluation Research Group, Institute of Applied Health Research,  
28 University of Birmingham, Birmingham, UK and NIHR Birmingham Biomedical Research Centre, University  
29 Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK

30  
31 Davenport C, Senior Clinical Lecturer, Test Evaluation Research Group, Institute of Applied Health Research,  
32 University of Birmingham, Birmingham, UK and NIHR Birmingham Biomedical Research Centre, University  
33 Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK

34  
35 Geppert J, Research Fellow, Warwick Medical School, University of Warwick, Coventry, UK

36  
37 Harris IM, Research Fellow, Test Evaluation Research Group, Institute of Applied Health Research, University of  
38 Birmingham, Birmingham, UK

39  
40 Osokogu O, Research Fellow, Warwick Medical School, University of Warwick, Coventry, UK

41  
42 Skrybant M, Public Involvement and Engagement Lead and Public Contributor, Institute of Applied Health  
43 Research, University of Birmingham, Birmingham, UK and NIHR Applied Research Collaboration West Midlands

44  
45 Deeks JJ, Professor of Biostatistics, Test Evaluation Research Group, Institute of Applied Health Research,  
46 University of Birmingham, Birmingham, UK and NIHR Birmingham Biomedical Research Centre, University  
47 Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK

48  
49  
50  
51 Correspondence to: Sian Taylor-Phillips [s.taylor-phillips@warwick.ac.uk](mailto:s.taylor-phillips@warwick.ac.uk)

52  
53 Warwick Medical School  
54 University of Warwick  
55 Coventry  
56 CV4 7AL

57  
58  
59 Word count: 4344  
60

## ABSTRACT

**Objectives:** To assess the accuracy and completeness of information provided by websites selling home self-sampling and testing kits for COVID-19.

**Design:** Cross-sectional observational study.

**Setting:** All websites (n=27) selling direct to user home self-sampling and testing for COVID-19 (41 tests) in the UK (39 tests) and US (2 tests) identified by a website search on 23<sup>rd</sup> May 2020.

**Main outcome measures —** Thirteen predefined basic information items to communicate to a user, including who should be tested, when and how testing should be done, test accuracy, and interpretation of results.

**Results:** Many websites did not provide the name or manufacturer of the test (32/41; 78%), when to use the test (10/41; 24%), test accuracy (12/41; 29%), and how to interpret results (21/41; 51%). Sensitivity and specificity were the most commonly reported test accuracy measures (either reported for 27/41 (66%) tests); we could only link these figures to manufacturers' documents or publications for four (10%) tests. Predictive values, most relevant to users, were rarely reported (five [12%] tests reported positive predictive values). For molecular virus tests, 9/23 (39%) websites explained that test positives should self-isolate, and 8/23 (35%) explained that test negatives may still have the disease. For antibody tests, 12/18 (67%) websites explained that testing positive does not necessarily infer immunity from future infection. Seven (39%) websites selling antibody tests claimed the test had a CE mark, when they were for a different intended use (venous blood rather than finger-prick samples).

**Conclusions:** At the point of online purchase of home self-sampling COVID-19 tests, users in the UK are provided with incomplete, and in some cases misleading information on test accuracy, intended use and test interpretation. Best practice guidance for communication about tests to the public should be developed and enforced for online sales of COVID-19 tests.

### Strengths and Weaknesses

- We believe this is the first research on accuracy of information provided by websites selling tests for COVID-19, where users may put themselves or others at increased risk of transmission if results are misinterpreted.
- We duplicated processes of searching and data extraction to minimise bias
- Using pre-specified criteria, we found evidence that websites selling home self-sampling COVID-19 tests provided incomplete and inaccurate information on test accuracy and interpretation of test results at the point of purchase.
- We developed basic guidance on what should be communicated when selling tests, including the type of test; situations when the test should be used; the time when the test should be done and details of how it should be done; the name of the test and details from clinical accuracy studies; evidence of compliance with regulatory approvals; explanation of test results using accessible and relevant metrics such as predictive values; and guidance to the interpretation and actions based on results.
- We only included websites from the UK and US, so whilst the principles of what should be communicated apply to all countries, the results about data completeness are not generalisable beyond the UK and US.

## INTRODUCTION

The 2019 novel coronavirus (COVID-19) pandemic has resulted in national population measures such as restricted movement ('lockdown'), and mass testing programmes. Testing is regarded as critical to manage the pandemic - the two main test types available being molecular virus tests (to detect current infection) and antibody tests (to detect previous infection). The World Health Organization (WHO) recommends polymerase chain reaction (PCR)-based molecular virus testing of symptomatic individuals to detect current COVID-19 infection,<sup>1</sup> to enable identification and isolation of confirmed cases, and tracing of those exposed for further testing. However, due to the sensitivity for a single PCR test being as low as 70%,<sup>2</sup> the WHO states that even two consecutive negative PCR tests do not rule out infection with COVID-19.<sup>1</sup> Antibody tests are not recommended for individual use by the WHO, because we do not yet understand whether presence of antibodies infers immunity from future infection. Their sensitivity has been estimated at around 80-90%, thus there is also a risk of false negatives.<sup>3</sup> Timing of testing is critical for both tests: molecular tests are thought to be most accurate when used within five days of the onset of symptoms,<sup>4</sup> antibody tests are most accurate two or more weeks after onset of symptoms.<sup>3</sup>

There are now multiple websites selling both molecular virus tests and antibody tests outside of national testing programmes. To ensure appropriate use, interpretation and actions following testing, it is necessary for tests to be sold with clear communication about who should use each test, when and how samples should be taken, and the implications of positive and negative results. Previous research investigating direct to user sales of genetic testing found that the information provided was incomplete, particularly the implications of test results and limitations of testing, and was not always in an accessible and understandable format.<sup>5-7</sup>

Direct to user sale of tests are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK and the Food and Drug Administration (FDA) in the US. Europe<sup>8</sup> and the USA<sup>9</sup> operate a risk based regulation for in vitro diagnostic devices (IVDs) which depends on the intended use of the test and indications for use. IVDs for *home testing* fall into higher risk categories reflecting the fact they are initiated, performed and interpreted without professional guidance and require evidence that lay users correctly use the test and understand test results. Lay user studies are required as the basis for the instructions for use (IFU) document for the IVD.<sup>10</sup> *Home sampling* tests are different from *home testing* as they receive approval based on home collected specimens with the test analysis being undertaken by professionals. At the time of writing, there were no COVID-19 antibody tests with a CE mark for either home sampling or home testing<sup>11</sup> (the two COVID-19 antibody tests purchased by the UK Government are approved for use in venous but not finger-prick blood samples) whilst several molecular virus tests have regulatory approval for home *sampling* and are being used in the UK track and trace programme.<sup>12</sup> Most websites selling COVID-19 tests would be classified by the MHRA as 'distributors', which gives clear obligations to supply the information provided by manufacturers with the test, but no specific guidance around communication on the website at the point of sale. Such claims are covered by the Advertising Standards Agency. In the US, there are no COVID-19 antibody tests with regulatory approval for home *testing* but four molecular (PCR) virus tests that have approval for home *sampling*<sup>13</sup> where the appropriateness of the test purchase is assessed by a professional either pre-purchase or following a purchase request.

We analysed the information given to individuals considering purchasing a molecular virus or antibody COVID-19 test online for home self-sampling. We chose to review tests for sale in both the UK and US to cover two different regulatory systems with contrasting health services. We recorded information regarding who should be tested and when, claims about test accuracy, and information

1  
2  
3 about how to interpret results. As the MHRA instigated a withdrawal of sales of antibody tests based  
4 on finger-prick blood samples on May 29<sup>th</sup> 2020 where tests require venous blood samples,<sup>11</sup> we also  
5 evaluated how test vendors have responded.  
6

## 7 **METHODS**

8  
9 Our research question was how complete, accurate and informative is the information that online  
10 websites selling home self-sampling and testing for COVID-19 provide to the public?  
11

### 12 **Identification of websites**

13 The search was designed to identify a representative sample of websites and online advertisements  
14 which would be seen by an individual searching for a non-specific COVID-19 test. We aimed to  
15 identify websites selling home self-sampling and testing for COVID-19 using molecular virus and/or  
16 antibody tests directly to users. Two researchers performed the searches independently on the  
17 same day (23<sup>rd</sup> May 2020) using the Google search engine in incognito mode in Google Chrome, with  
18 geo-locations for the UK and for the USA. In order to emulate a simple search for a non-specific  
19 coronavirus test, the search terms were (coronavirus OR covid-19 OR covid19) AND (test OR testing  
20 OR kit). Two researchers independently screened all results against the inclusion criteria,  
21 disagreements were resolved by a third researcher. For the UK search, we included websites moved  
22 to the top of the search results through advertisements, in order to mirror what a user would have  
23 seen on that day.  
24  
25

### 26 **Inclusion criteria**

27 We included websites selling molecular virus and/or antibody tests for COVID-19 direct to users in  
28 either the US or UK. We included point-of-care and laboratory-based tests, with the proviso that the  
29 sample was taken at home by the individual themselves. We excluded tests with assisted sampling  
30 (e.g. drive-through testing), or where part of the testing process before purchase included video,  
31 telephone or in-person contact with a medical professional (as we could not objectively assess the  
32 information content of such interactions). We included websites selling tests both via direct  
33 purchase and insurance funding, but excluded local or national government websites providing tests  
34 (including Public Health England [PHE] and the UK National Health Service [NHS]), and websites  
35 providing tests as part of a research study. We included all eligible tests, including where a single  
36 website sold multiple eligible tests. We excluded websites with a minimum order of more than a  
37 single test, as these targeted suppliers rather than individual users.  
38  
39  
40

### 41 **Data extraction**

42 We extracted information about the test manufacturer and type of test; when testing was  
43 recommended; claims made about test accuracy; the advice given about changing behaviour in light  
44 of test results; accreditation; and the test cost. We assessed the information provided against a  
45 predefined list of items which we would expect to be communicated to a person considering  
46 purchasing a test for COVID-19, detailed in Table 1.  
47

48 We extracted claims made about regulatory approval of the tests, in particular CE-IVD approval in  
49 the UK and FDA approval in the US, and where possible compared claims to the actual approval  
50 status for the test. We also extracted claims made about approval from non-regulatory bodies such  
51 as PHE and the NHS.  
52

53 Website contents were extracted between 23<sup>rd</sup> and 28<sup>th</sup> May 2020. One researcher extracted data  
54 from each website onto a predefined data extraction form, and downloaded the website as an  
55 image file. A second researcher checked each extraction using the pdf copy to exclude temporal  
56 changes.  
57

### 58 **Patient and public involvement**



A public contributor (MS), with both experience of being involved in research and leading public involvement in research, provided input into this project. MS has an interest in communicating scientific information to lay audiences. The rapid timeframes in which the research was conducted limited the scope for more comprehensive public involvement. MS contributed to discussions, paper drafts and is included as a co-author.

Ethics approval was not required for this review of publicly available documents.

## RESULTS

For the UK our Google searches retrieved 550 results, and for the US they retrieved 430 results. After the first round of sifting by 2 reviewers 46 potentially eligible websites were identified. Of these 19 websites were later excluded, 13 of which only sold in quantities greater than one or to laboratories/hospitals/workplaces, 5 who incorporated contact with a health professional before the sale, and one which was withdrawn from sale between the search and extraction. We identified 23 molecular virus testing services<sup>14-36</sup> and 18 antibody testing services<sup>14-16 18 19 21 25 26 28 29 31-34 37-40</sup> meeting the inclusion criteria, sold via 27 websites (25 from the UK<sup>14-34 37-40</sup> and 2 from the US<sup>35 36</sup>). One website<sup>40</sup> did not appear in the main search, but was mentioned in many UK news articles, so was included in the cohort. Only two websites using home sampling were identified in the US, the first and second to be approved by the FDA for this use.<sup>35 36</sup> Basic characteristics of the websites and tests are given in Supplementary Table 1.

The websites consisted of 13 private health clinics,<sup>14-17 20 21 24-26 29 36 38 39</sup> four pharmacies,<sup>30 32 34 40</sup> four suppliers of a range of direct to consumer testing online,<sup>18 22 31 37</sup> three laboratories,<sup>23 33 35</sup> two online sexual health specialists<sup>19 27</sup> and one supplier of beauty treatments.<sup>28</sup> All 23 molecular virus tests were laboratory-based tests with home sampling. Of the 18 antibody tests, 17 were laboratory-based tests with home self-sampling, and one was a point-of-care test.<sup>38</sup> The test manufacturer was identifiable for 9/41 (22%) tests, further details are provided in Supplementary Figure 1.

The mean cost of molecular virus testing was £168 (range £65 to £279) in the UK and \$135 (range \$119 to \$150) in the US. The mean cost of antibody tests was £87 (range £55 to £130) in the UK.

The proportion of websites which met each of the criteria for clear communication (outlined in Table 1) is shown in Figure 1, and examples of reporting are given in Box 1.

### Explaining which test and when to test

All 27 websites stated whether the 41 tests for sale were molecular virus tests or antibody tests, of which 40/41 described the test clearly. Guidance on timing of taking the molecular virus tests and the antibody tests was provided by 15/23 (65%)<sup>15 17-21 25-27 29-31 34-36</sup> and 16/18 (89%)<sup>15 16 18 19 21 25 26 28 29 31 33 34 37-40</sup> websites, respectively. Recommendations on timing and variation in timing of sampling are detailed in Figure 2, with several contrary to current advice or opinion.<sup>4</sup>

### Test accuracy and interpretation

Of the 41 tests for sale, the websites reported a measure of test accuracy (sensitivity, specificity, positive or negative predictive value) for 27 (66%) tests: 16/18 (89%) for antibody tests<sup>14 15 18 19 21 25 26 28 29 31 33 34 37-40</sup> and 11/23 (48%) for molecular tests.<sup>14 17 20-22 25 26 33-36</sup> An additional 10/41 (24%) tests (two antibody<sup>16 32</sup> and eight molecular tests<sup>15 16 18 19 23 27 29 32</sup>) only reported test performance using unclear terms such as 'accuracy' or 'reliability', for example "This test has a 99.9% accuracy"<sup>19</sup> and "This test offers 99.9% reliability".<sup>29</sup> Tests with unclear performance values may be referring to analytical performance, such as "Our test is sensitive to fewer than 100 copies of the target viral RNA, making it a highly accurate test."<sup>32</sup> For two (5%) molecular tests, no text or values referring to accuracy were reported on the websites.<sup>24 31</sup>



Sensitivity and specificity were the most commonly reported accuracy measures, provided for 27/41 (66%)<sup>14 15 17-22 25 26 28 29 31 33-40</sup> and 22/41 (54%)<sup>15 17 19-22 25 26 28 29 31 33-37 39 40</sup> tests, respectively. Sensitivity estimates ranged from 95% to 100% for antibody tests (n=16)<sup>14 15 18 19 21 25 26 28 29 31 33 34 37-40</sup> and 97.5% to 100% for molecular tests (n=11)<sup>14 17 20-22 25 26 33-36</sup>; specificity estimates ranged from 97.5% to 100% for antibody tests (n=13)<sup>15 19 21 25 26 28 29 31 33 34 37 39 40</sup> and were reported as 100% for all molecular tests (n=9).<sup>17 20-22 25 26 34-36</sup> Five of the 41 tests (13%; two antibody tests<sup>28 31</sup> and three molecular<sup>14 20 33</sup> tests) provided an estimate or statements of sensitivity and/or specificity under conditions of perfect use rather than pragmatic use, for example *“If there are any coronavirus on your swab it will definitely find it”*.<sup>33</sup>

No websites directly referred to positive predictive values (PPV), but they were indirectly reported for 5/41 (12%) tests.<sup>25 25 21 20 40</sup> Two antibody<sup>25 40</sup> and three molecular tests<sup>25 21 20</sup> made a statement about the lack of false positives (implying a PPV of 100%), for example *“if it shows a positive result, it can only be for COVID-19”*.<sup>25</sup> No cross-reactivity (meaning the test would not identify other viruses, only COVID-19 virus) was referred to by websites for 13/41 (32%) tests (five antibody<sup>16 25 33 34 40</sup> and eight molecular tests<sup>17 20-22 25 26 28 34</sup>). Negative predictive value (NPV) was not referred to by any websites; however, statements implying that the NPV was less than 100% were given for 4/41 (10%) available tests (two antibody<sup>25 31</sup> and two molecular tests<sup>20 35</sup>), for example *“The test can sometimes show a negative result even if you are infected SARS-CoV-2, the virus that causes COVID-19”*.<sup>35</sup>

The number of samples used to generate accuracy data were given for 5/41 (12%) tests; two antibody tests<sup>31 33</sup> and three molecular tests.<sup>22 35 36</sup> Accuracy data were linked to a journal publication for only 1/41 (2%) test.<sup>33</sup>

Information on interpreting both positive and negative molecular virus test results was presented for 4/23 (17%) websites.<sup>20 33-35</sup> Twelve of the 18 (67%) websites selling antibody tests informed potential customers prior to purchase that a positive antibody test may not infer immunity from future infection<sup>14 16 18 21 25 28 32-34 37 39 40</sup> (Figure 1).

Where tests could be identified, we checked accuracy claims against data from published papers, pre-prints (based on information obtained from searches from ongoing Cochrane reviews for these tests) and manufacturer’s data in the Instructions for Use (IFU) sheet for each test (Table 2). Four websites reported clinical performance data for the Abbott IgG antibody test: two<sup>31 33</sup> quoted the performance figures from the IFU<sup>41</sup>, for the other two<sup>26 29</sup> no exact match with available studies could be made. Of the four molecular tests, no performance data were available for the Randox test<sup>23</sup> (including in the IFU<sup>42</sup>), no direct match of clinical performance results could be made for the website selling the Primerdesign genesig PCR assay<sup>22</sup> (where the IFU only reported data from contrived samples<sup>43</sup>), whereas the data reported by US websites<sup>35 36</sup> selling the LabCorp and Rutgers PCR tests, respectively, matched data from the manufacturers’ IFUs.<sup>44 45</sup>

### Claims about Regulatory Approval and Endorsement

Across the 25 UK websites, there were 17 antibody tests for home sampling,<sup>14-16 18 19 21 25 26 28 29 31-34 37 39 40</sup> one antibody test for home testing<sup>38</sup> and 21 molecular tests for home sampling<sup>14-34</sup> for sale. There was no mention of regulatory approval or endorsement for 18/39 (46%) tests, seven antibody tests<sup>14 16 26 28 32 39 40</sup> and 11 molecular tests<sup>14 16 18 19 22-24 27 29-31</sup> (see Supplementary Table 1).

For home sampling antibody tests, 7/17 (41%) included a statement that the test had a CE mark<sup>15 19 21 25 33 34 37</sup> and 7/17 (41%) websites included a clear statement that the test had endorsement from a policy making body such as Public Health England, the NHS or the UK or other European government.<sup>15 18 21 29 31 33 34</sup> This is despite the fact that currently no COVID-19 antibody tests have regulatory approval for home sampling or home testing. Claims being made about home sampling tests were based on approved test use by health professionals using venous rather than finger-prick samples:

1  
2  
3 *"All of our home test kits are CE-marked. This is one of the two IgG tests approved by the*  
4 *Government for UK use."*<sup>15</sup>  
5  
6

7 One website<sup>38</sup> claimed it had regulatory approval for its home *testing* antibody test:

9 *"Our test has been accepted by Medicines and Healthcare products regulatory Agency (MHRA),*  
10 *which means that it can be applied across the EU including UK. We confirm our product can meet the*  
11 *requirement of In vitro Diagnostic Medical Devices Directive (98/79EC) and standards complying with*  
12 *CE Declaration of Conformity."*<sup>38</sup>  
13

14 Five of 21 (24%) UK websites selling molecular virus tests for home sampling included a statement  
15 that they had regulatory approval<sup>15 21 25 26 33</sup> and 6 (29%) websites<sup>17 20 28 32-34</sup> claimed approval from a  
16 policy making body for this intended use. The manufacturer or name of the molecular tests for  
17 which websites were claiming regulatory approval or endorsement could not be identified. Only for  
18 two websites selling molecular tests<sup>22 23</sup>, the test manufacturer could be identified, neither of which  
19 made any claims about regulation or endorsement. One of these tests<sup>23</sup> is mentioned by the UK  
20 government as part of its COVID-19 testing strategy<sup>46</sup> and the other<sup>22</sup> was one of the tests which was  
21 independently evaluated by PHE.<sup>47</sup>  
22  
23

24 Both USA websites selling molecular viral tests<sup>35 36</sup> have approval from the FDA for home sampling  
25 during the COVID-19 pandemic. These websites included information about the eligibility checks that  
26 purchasers would need to undergo either prior to purchase or prior to test processing.  
27  
28

29 We reviewed the 18 UK websites selling home COVID-19 antibody tests<sup>14-16 18 19 21 25 26 28 29 31-34 37-40</sup> on  
30 11<sup>th</sup>/12<sup>th</sup> June 2020 after the MHRA had instructed sales of these tests to cease because of the lack  
31 of approval for the tests using finger-pick samples.<sup>11</sup> We found two websites<sup>32 38</sup> that appeared to  
32 still be selling finger-prick tests, four<sup>14 21 28 31</sup> had switched to providing a venous blood sampling  
33 service, two<sup>18 33</sup> required the purchaser to find their own phlebotomist to draw a blood sample to  
34 send, six<sup>15 16 19 25 34 40</sup> simply stated that tests were out of stock and were unavailable, whilst four<sup>26 29</sup>  
35 <sup>37 39</sup> reported the MHRA guidance and indicated that they had suspended sales (Table 3).  
36  
37  
38  
39

## 40 DISCUSSION

41 We identified 27 websites selling COVID-19 tests direct to the public, 25 in the UK but only two in  
42 the US, which may be explained by the FDA stipulations requiring clinician involvement in the testing  
43 process. We observed that many websites failed to provide complete information on the name and  
44 manufacturer of the test (no information for 32/41 tests), when to use the test (no information for  
45 10/41 tests), the accuracy of the test (no information for 12/41 tests), and how to interpret results  
46 (no information for 21/41 tests), which will hinder the public making informed choices about testing,  
47 using tests correctly and understanding what test results mean. Without adequate and correct  
48 information the public may purchase the wrong or a poor test, or use the test in the wrong way or at  
49 the wrong point in time. These errors or application will increase their chances of getting an  
50 erroneous test result. Even when used properly, few websites assisted users in interpreting test  
51 results and understanding their inherent uncertainty.  
52  
53

54 This rapid evaluation was designed to provide timely results in the context of a fast-moving global  
55 pandemic. The search was not designed to be exhaustive, rather to represent what a person typing  
56 "coronavirus test" or similar into a Google search would have retrieved. Using different phrases such  
57 as "coronavirus antibody test" would have identified additional websites, but there is no reason to  
58  
59  
60

1  
2  
3 suspect that they would be different from those summarised here. The timing of the search and data  
4 extraction will have affected results. Data extraction was shortly before the UK MHRA clarified that  
5 antibody tests were not approved for finger-prick samples, only for venous samples. The search only  
6 identified two US websites selling tests with home sample collection, but at the point of going to  
7 press eight tests are now approved on the FDA website.<sup>48</sup> The criteria that we used to assess  
8 completeness of communication (detailed in Table 1) were defined *a priori*, but due to time  
9 constraints a formal process for developing these was not followed. However, all key elements of  
10 the search, selection and data extraction processes were undertaken independently by two  
11 researchers, reducing the possibility of errors. We only assessed information provided prior to  
12 purchase, as complete information should be given at this stage to inform the purchasing decision.  
13 However, further information would have been given after purchase, for example within the  
14 instructions for use, which was beyond the scope of this paper.

15  
16  
17  
18 The issues we have identified are examples of poor and misleading practice, and some merit further  
19 investigation by the MHRA and Advertising Standards Authority. At the time of going to press two  
20 antibody tests remained on sale and we have reported these to the MHRA. The communication of  
21 test accuracy appears to contravene advertising standards in the UK. The five websites that reported  
22 PPV of 100% contrary to the wider evidence base, and all websites making accuracy claims which is  
23 not linked to supporting evidence appear to contravene section 12.1 of the ASA code,<sup>49</sup> which states  
24 that objective claims must be backed by evidence. Further, websites provided specificity and  
25 sensitivity, or general claims of ‘accuracy’ rather than positive and negative predictive values  
26 explained in lay terms, and the ASA have previously ruled against this practice as misleading in the  
27 case of non-invasive prenatal testing for trisomies.<sup>50</sup> Finally, the lack of complete information on the  
28 implications of positive and negative test results does not appear to be covered by any UK  
29 regulation, perhaps because the ASA 12.2.1<sup>49</sup> prohibit diagnosis by post or email, and so this  
30 information is intended to be provided by contact with a healthcare professional. Whilst such  
31 contact with a health professional is happening in the US it does not appear to be in the UK.  
32 Regulation of product labelling provides a means to oversee information communicated for self-  
33 testing products bought in person, but there is currently no equivalent for online testing services in  
34 the UK. This gap in regulation could be solved by expanding the responsibility of the MHRA to  
35 include communication by ‘distributors’ at the point of online purchase, working collaboratively with  
36 the Advertising Standards Agency. There was a large variation in price of testing in the UK, and in  
37 many cases these differences do not appear to be justified by differences in the service provided.  
38 Greater regulation and standardisation of website claims may reduce this price differential by  
39 making comparisons between websites easier, and removing unsubstantiated claims.

#### 45 Key Communication Requirements

46  
47 It is important that all test users are given adequate and appropriate information to help them make  
48 safe and informed choices. We identified five key communication issues with websites selling direct  
49 to consumer home-sampling COVID-19 tests. All five of these issues may be improved by developing  
50 a basic framework of what information should be provided, and standard ways to present such  
51 information. This would also facilitate comparison between websites.

##### 52 53 54 1) *The type of test and the questions which it can help address.*

55  
56 It is essential that companies selling tests identify the type of test, and the situations in which it is  
57 appropriate to order such a test. Whilst websites were clear whether they were selling molecular or  
58 antibody tests, they also need to indicate the situations when it is appropriate to order a molecular  
59 “swab” test or an antibody “blood” test in order to select the correct one. The two US websites  
60

1  
2  
3 utilised questionnaires recording symptoms and exposure which were reviewed by clinicians prior to  
4 tests being despatched which provides a more rigorous check on whether the test request is  
5 sensible.  
6

7  
8 *2) How and when the test should be used.*

9 Both molecular and antibody tests need to be used at different time points in the disease course.  
10 The sensitivity of both types of tests will fall if used at the wrong time point (sensitivity of 31% for  
11 antibody tests in the first week since onset of symptoms<sup>3</sup>), substantially increasing the risks of  
12 infection or antibody response being undetected. Recommended time points when samples should  
13 be taken were absent for 10/39 UK tests (26%). Some timing statements were misleading,  
14 suggesting using the test at time points which are known to be too early or too late. Some websites  
15 stated dates based on time since exposure, others since symptom onset which is median 5 days after  
16 exposure. Both are required to be able to advise both asymptomatic patients and patients with  
17 unknown exposure when they should order and use the tests.  
18

19  
20  
21 Websites must also describe the full testing process and clearly indicate what is required of users to  
22 complete testing. For example, two antibody websites currently indicate that purchasers will need  
23 to identify individuals qualified to take venous blood samples, which is impractical for most people.  
24

25  
26 *3) The test name, evidence of its accuracy, and evidence of its regulatory approval for the  
27 purpose to which it is put.*

28 The majority of tests were for sale by third parties, ranging from healthcare providers to beauty  
29 treatment specialists. In most cases (32/41; 78%) it was not possible to identify the test being used  
30 or the manufacturer. This does not allow the individual to know the product that they are buying,  
31 and precludes the opportunity for the user to verify its regulatory status and the claims being made.  
32

33 Information on test accuracy was absent or uninterpretable for 12/41 (29%) tests. Numerical  
34 accuracy claims could only be matched to published evidence for 4/41 (10%) of tests. In these  
35 instances, figures most closely matched those from the manufacturers' Instructions for Use leaflets,  
36 which tended to report the highest observed values of sensitivity and specificity, and were based on  
37 studies more akin to analytic validity than clinical validity evaluations. Accuracy measures from  
38 analytic validity studies should not be assumed to give a good representation of test accuracy when  
39 applied in practice to the public. A wide range of terms were used, several of which did not have a  
40 clear meaning. It appeared that test accuracy data is not available at all for some tests (Randox)<sup>42</sup>, or  
41 only based on contrived samples (Primerdesign)<sup>43</sup> and not on real patients. For molecular COVID-19  
42 tests, no clinical performance data were available that were based on self-sampled swab tests.  
43 Withholding the fact that there is no patient based evidence of the accuracy of these tests from the  
44 public is unacceptable. It is important that the reported accuracy is based on all reviewed evidence  
45 and not selected results, and clearly explains how applicable the evidence is to the public.  
46

47  
48 Naming tests is essential to be able to check their regulatory status. Seven of 18 (39%) UK websites  
49 selling antibody tests inappropriately claimed CE marking, when the CE marking was for a different  
50 intended use (venous rather than finger-prick blood samples). Antibody tests are not approved for  
51 home use in the US, and none were found in our search. The UK regulator acted after we had  
52 reviewed UK websites, clarifying that antibody tests which are approved for the use with venous  
53 samples should not be sold for the use with finger-prick samples. However, 2/18 remain available for  
54 online sale at the point of going to press (accessed 11<sup>th</sup> to 12<sup>th</sup> June 2020). The molecular tests we  
55 could identify are approved for home sampling, however, the name and manufacturer was not  
56 identifiable for most websites.  
57  
58  
59  
60

#### 4) *What test results mean.*

Research concerning the communication of test accuracy evidence is limited and is largely restricted to self-selected, professional and postgraduate student groups.<sup>51</sup> Communication of test accuracy evidence is complex for several reasons. Research has highlighted the importance of communicating the potential consequences of positive and negative test results (use of predictive values) and the importance of contextualising estimates of accuracy with reference to a healthcare setting (for example hospital in patient, hospital outpatient, community).<sup>52 53</sup> Presenting test accuracy as frequencies rather than as probabilities improves understanding.

To interpret results, test users need to know how to interpret positive and negative test results (predictive values), not the proportion of cases detected (sensitivity) and non-cases correctly diagnosed (specificity). Positive predictive value was only reported for 5/41 (12%) tests, and in all five they claimed it was 100% which is inconsistent with the broader evidence base. Negative predictive value was not reported at all.

Most websites gave insufficient information regarding interpreting test results. Only 8/23 (35%) websites explained that a negative molecular virus test does not rule out COVID-19, and only 12/18 (67%) explained that a positive antibody test does not necessarily infer immunity from future COVID-19 infection or transmission.

#### 5) *Decisions which could be made based on the test results.*

Misunderstanding of the implications of test results could mean that individuals put themselves or others at risk of infection in the mistaken belief that they do not have COVID-19, or that they are immune to COVID-19. This last category probably has the greatest potential for harm. Clear communication about the meaning of test results as detailed above should be linked to evidence-based guidance about behaviour modification in light of test results. We found widespread evidence of websites failing to provide such evidence-based guidance, and some cases of websites actively suggesting unsafe behaviour.

## CONCLUSIONS

At the point of online purchase of home self-sampling COVID-19 tests, users in the UK are provided with incomplete, and in some cases misleading information on test application, accuracy and interpretation. Many websites omit trustworthy guidance on the timing of tests, the interpretation of positive and negative test results, and the implications of results. Best practice guidance for communication about tests to the public should be developed and the role of the regulator in enforcing complete and accurate information should be reviewed. This should be underpinned by robust collaborative qualitative research exploring how members of the public interpret information and measures of accuracy, thus informing how it can be provided in a way that is clear, complete and accessible

## References

1. World Health Organization. Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: interim guidance, 19 March 2020. Geneva: World Health Organization, 2020.
2. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, et al. FALSE-NEGATIVE RESULTS OF INITIAL RT-PCR ASSAYS FOR COVID-19: A SYSTEMATIC REVIEW. *medRxiv* 2020:2020.04.16.20066787. doi: 10.1101/2020.04.16.20066787
3. Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. *Cochrane Database of Systematic Reviews* 2020(6)



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
4. National Health Service (NHS). Ask for an antigen test to check if you have coronavirus now [updated 17 June 2020. Available from: <https://www.nhs.uk/conditions/coronavirus-covid-19/testing-and-tracing/ask-for-a-test-to-check-if-you-have-coronavirus/> accessed 19/06/2020.
5. Covolo L, Rubinelli S, Ceretti E, et al. Internet-Based Direct-to-Consumer Genetic Testing: A Systematic Review. *J Med Internet Res* 2015;17(12):e279. doi: 10.2196/jmir.4378 [published Online First: 2015/12/19]
6. De S, Pietila AM, Iso-Touru T, et al. Information Provided to Consumers about Direct-to-Consumer Nutrigenetic Testing. *Public Health Genomics* 2019;22(5-6):162-73. doi: 10.1159/000503977 [published Online First: 2019/11/30]
7. Singleton A, Erby LH, Foisie KV, et al. Informed choice in direct-to-consumer genetic testing (DTCGT) websites: a content analysis of benefits, risks, and limitations. *J Genet Couns* 2012;21(3):433-9. doi: 10.1007/s10897-011-9474-6 [published Online First: 2011/12/24]
8. The European Parliament and the Council of the European Union. REGULATION (EU) 2017/746 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU 2017 [Available from: <https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32017R0746&from=EN#d1e4364-176-1> accessed 30/05/2020.
9. U.S. Food & Drug Administration. Federal Food, Drug and Cosmetic Act (FD&C Act) Chapter V: Drugs and Devices 2018 [Available from: <https://www.fda.gov/regulatory-information/federal-food-drug-and-cosmetic-act-fdc-act/fdc-act-chapter-v-drugs-and-devices> accessed 30/05/2020.
10. Medicines & Healthcare products Regulatory Agency. Guidance for notified bodies on the regulation of IVDs for self-testing 2012. [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/377885/Guidance\\_for\\_notified\\_bodies\\_on\\_the\\_regulation\\_of\\_IVDs\\_for\\_self-testing.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/377885/Guidance_for_notified_bodies_on_the_regulation_of_IVDs_for_self-testing.pdf) (accessed 02/06/2020).
11. Medicine & Healthcare products Regulatory Agency. Guidance For industry and manufacturers: COVID-19 tests and testing kits. Updated 29 May 2020 [Available from: <https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work/for-industry-and-manufactures-covid-19-tests-and-testing-kits> accessed 30/05/2020.
12. Medicine & Healthcare products Regulatory Agency. Guidance For patients, the public and professional users: a guide to COVID-19 tests and testing kits. [Available from: <https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work/for-patients-the-public-and-professional-users-a-guide-to-covid-19-tests-and-testing-kits> accessed 04/06/2020.
13. U.S. Food & Drug Administration. Emergency Use Authorizations [updated 06/04/2020. Available from: <https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd> accessed 30/05/2020.
14. CityDoc. Coronavirus Home Testing Kits [Available from: <https://www.citydoc.org.uk/covid-19-home-testing-kit/> accessed 25/05/2020.
15. DoctorCall. Covid-19 Home Testing Kits [Available from: <https://www.doctorcall.co.uk/private-gp-services/coronavirus--covid-19--testing> accessed 24/05/2020 and 26/05/2020.
16. Summerfield Healthcare. Covid-19 Test kits and Covid-19 Test Antibody kits [Available from: <https://www.summerfieldhealthcare.co.uk/corona-virus-testing/> accessed 24/05/2020.
17. London Doctors Clinic. Services - Private Coronavirus Test [Available from: <https://www.londondoctorsclinic.co.uk/services/private-coronavirus-test/> accessed 25/05/2020.

18. Blue Horizon Medicals. COVID-19 Home Coronavirus Test Kits [Available from: <https://bluehorizonbloodtests.co.uk/collections/covid-19-coronavirus-tests> accessed 24/05/2020.
19. Better2Know. Covid-19 testing [Available from: <https://www.better2know.co.uk/page/covid-19> accessed 26/05/2020.
20. Private Harley Street Clinic. COVID-19 PCR Home Sample Kit - Currently infected [Available from: <https://privateharleystreetclinic.com/products/covid-19-test> accessed 24/05/2020.
21. Qured. Covid-19 PCR and Antibody Tests Now Available [Available from: <https://qured.com/covid-19-testing/> accessed 24/05/2020 and 25/05/2020.
22. Rightangled. COVID-19 Test [Available from: <https://rightangled.co/product/covid-19-test> accessed 24/05/2020.
23. Randox Health. COVID-19 Home Testing Kit [Available from: <https://www.randoxhealth.com/product/coronavirus-covid-19-home-testing-kit/> accessed 26/05/2020.
24. SameDayDoctor. COVID-19 Abbott Coronavirus testing [Available from: <https://samedaydoctor.org/service/covid-19-coronavirus-antibody-testing/> accessed 24/05/2020.
25. Zava. Coronavirus antibody and swab testing service [Available from: <https://www.zavamed.com/uk/coronavirus-service.html> accessed 22/05/2020.
26. TheOnlineClinic. Coronavirus (COVID-19) [Available from: <https://www.theonlineclinic.co.uk/coronavirus-testing.asp> accessed 27/05/2020.
27. Family Planning Association (FPA). Covid-19 Coronavirus Home Test Kit [Available from: <https://www.fpa.org.uk/product/new-covid-19-coronavirus-home-test-kit> accessed 26/05/2020.
28. Antibody Solutions. Covid-19 Home IgG Sample Collection Test Kit and Lab Test [Available from: <https://antibodyolutions.co.uk/> accessed 27/05/2020.
29. MyHealthcare Clinic. Coronavirus (COVID-19) Testing [Available from: <https://myhealthcareclinic.com/covid-19-purchase-tests/> accessed 24/05/2020.
30. MedExpress Enterprises Ltd. Coronavirus Testing - Home Sample Collection Kit [Available from: <https://www.medexpress.co.uk/testing/covid19/coronavirus-covid19-home-testing-kit-pcr> accessed 24/05/2020.
31. Atruchecks Ltd. Covid-19 tests - Private Covid-19 Clinical Testing Service [Available from: <https://www.atruchecks.com/category/covid-19-tests> accessed 27/05/2020.
32. PillDoctor. Covid-19 [Available from: <https://www.pilldoctor.co.uk/product-category/Covid-19> accessed 27/05/2020.
33. London Medical Laboratory. Coronavirus Antibody & PCR Tests - In Stock Now [Available from: <https://www.privatecoronavirustests.com/> accessed 24/05/2020.
34. Webmed Pharmacy Ltd. covid-19 tests [Available from: <https://webmedpharmacy.co.uk/buy/covid19testkit> accessed 23/05/2020.
35. Pixel by LabCorp. COVID-19 Test (At-Home Kit) [Available from: <https://www.pixel.labcorp.com/at-home-test-kits/covid-19-test> accessed 27/05/2020.
36. Hims Inc. COVID-19 Saliva Test [Available from: <https://www.forhims.com/covid-test> accessed 28/05/2020.
37. Medichecks.com Ltd. Coronavirus Antibody Blood Test [Available from: <https://medichecks.com/pages/coronavirus-antibody-blood-test-information> accessed 23/05/2020.
38. YourHealthFirst Clinic. Ten minute coronavirus self-testing kit [Available from: <https://www.yourhealthfirst.uk/our-services/covid-19-rapid-test/> accessed 25/05/2020.
39. Babylon. COVID-19 Antibody Test [Available from: <https://www.babylonhealth.com/coronavirus/covid-19-antibody-test> accessed 23/05/2020.



- 1
- 2
- 3
- 4 40. Superdrug. Coronavirus Antibody Test Service [Available from:  
5 <https://onlinedoctor.superdrug.com/coronavirus-antibody-test.html> accessed 28/05/2020.
- 6 41. Abbott Laboratories. SARS-CoV-2 IgG ARCHITECT. *Instructions for Use (IFU)* April 2020.  
7 <https://www.fda.gov/media/137383/download>.
- 8 42. Randox Laboratories Ltd. Extended Coronavirus Multiplex Array EV4418 User Manual.  
9 <https://static1.squarespace.com/static/568969badf40f3987cccc1d9/t/5e6912a5d041d92494d4fdc7/1583944358498/EV4418.doc.pdf>.
- 10 43. Primerdesign Ltd. Coronavirus (COVID-19) genesig® Real-Time PCR assay - For Emergency Use  
11 Authorization Only - Instructions for Use (IFU) Issue 1.02. 31 March 2020.  
12 <https://www.fda.gov/media/136309/download>.
- 13 44. U.S. Food & Drug Administration. ACCELERATED EMERGENCY USE AUTHORIZATION (EUA)  
14 SUMMARY - SARS-CoV-2 ASSAY (Rutgers Clinical Genomics Laboratory). 2020.  
15 <https://www.fda.gov/media/137776/download>.
- 16 45. U.S. Food & Drug Administration. ACCELERATED EMERGENCY USE AUTHORIZATION (EUA)  
17 SUMMARY - COVID-19 RT-PCR TEST(LABORATORY CORPORATION OF AMERICA). 2020.  
18 <https://www.fda.gov/media/136151/download>.
- 19 46. Department of Health & Social Care. Coronavirus (COVID-19) - Scaling up our testing  
20 programmes. Department of Health and Social Care. Published 04 April 2020.  
21 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/878121/coronavirus-covid-19-testing-strategy.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/878121/coronavirus-covid-19-testing-strategy.pdf) (accessed 11/06/2020).
- 22 47. National Infection Service (NIS) laboratories Public Health England. Rapid assessment of the  
23 Novacyt Primerdesign Coronavirus (COVID-19) genesig® Real-Time PCR assay. June 2020.  
24 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/889330/Rapid\\_assessment\\_Novacyt\\_Primerdesign\\_Coronavirus\\_COVID-19\\_Genesig.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/889330/Rapid_assessment_Novacyt_Primerdesign_Coronavirus_COVID-19_Genesig.pdf).
- 25 48. U.S. Food & Drug Administration. In Vitro Diagnostics EUAs: U.S. Food & Drug Administration;  
26 2020 [updated 18/06/2020. Available from: <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas> accessed 19/06/2020.
- 27 49. The Advertising Standards Authority Ltd. (ASA) and The Committee of Advertising Practice Ltd.  
28 (CAP). 12 Medicines, medical devices, health-related products and beauty products - CAP  
29 Code. 2020 [Available from:  
30 [https://www.asa.org.uk/type/non\\_broadcast/code\\_section/12.html](https://www.asa.org.uk/type/non_broadcast/code_section/12.html) accessed 20/06/2020.
- 31 50. The Advertising Standards Authority Ltd. (ASA) and The Committee of Advertising Practice Ltd.  
32 (CAP). Non-Invasive Prenatal Testing (NIPT) – A look at the ASA’s rulings. CAP News. 16 Jan  
33 2020 [Available from: <https://www.asa.org.uk/news/non-invasive-prenatal-testing-nipt-a-look-at-the-asa-s-rulings.html> accessed 20/06/2020.
- 34 51. Whiting PF, Davenport C, Jameson C, et al. How well do health professionals interpret diagnostic  
35 information? A systematic review. *BMJ Open* 2015;5(7):e008155. doi: 10.1136/bmjopen-2015-008155 [published Online First: 2015/07/30]
- 36 52. Whiting P, Leeflang M, de Salis I, et al. Guidance was developed on how to write a plain language  
37 summary for diagnostic test accuracy reviews. *J Clin Epidemiol* 2018;103:112-19. doi:  
38 10.1016/j.jclinepi.2018.07.008 [published Online First: 2018/07/24]
- 39 53. Whiting P, Davenport C. Understanding test accuracy research: a test consequence graphic.  
40 *Diagn Progn Res* 2018;2:2. doi: 10.1186/s41512-017-0023-0 [published Online First:  
41 2018/02/01]
- 42 54. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19)  
43 From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med*  
44 2020;172(9):577-82. doi: 10.7326/M20-0504 [published Online First: 2020/03/10]
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1  
2  
3 55. Bryan A, Pepper G, Wener MH, et al. Performance Characteristics of the Abbott Architect SARS-  
4 CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. *J Clin Microbiol* 2020 doi:  
5 10.1128/JCM.00941-20 [published Online First: 2020/05/10]  
6  
7 56. Phipps WS, SoRelle JA, Li Q-Z, et al. SARS-CoV-2 Antibody responses do not predict COVID-19  
8 disease severity. *medRxiv* 2020:2020.05.15.20103580. doi: 10.1101/2020.05.15.20103580  
9  
10 57. Public Health England. Evaluation of the Abbott SARS-CoV-2 IgG for the detection of anti-SARS-  
11 CoV-2 antibodies. Version of 8 June 2020. London, 2020:1-18.  
12  
13 58. Epitope Diagnostics Inc. EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit (KT-1032). *Instructions*  
14 *for Use (IFU)* May 2020. <http://www.epitopediagnostics.com/covid-19-elisa>.  
15  
16 59. Kruttgen A, Cornelissen CG, Dreher M, et al. Comparison of four new commercial serologic  
17 assays for determination of SARS-CoV-2 IgG. *J Clin Virol* 2020;128:104394. doi:  
18 10.1016/j.jcv.2020.104394 [published Online First: 2020/05/18]  
19  
20 60. Public Health England. Rapid assessment of the Randox Extended Coronavirus Multiplex Array  
21 assay. V01.20 ed. London, June 2020:1-5.  
22  
23 61. van Kasteren PB, van der Veer B, van den Brink S, et al. Comparison of seven commercial RT-PCR  
24 diagnostic kits for COVID-19. *J Clin Virol* 2020;128:104412. doi: 10.1016/j.jcv.2020.104412  
25 [published Online First: 2020/05/18]  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

peer review only

**Box 1: Examples of clear/accurate and unclear/potentially misleading website content**

Information item	Example of unclear/potentially misleading information	Example of clearer and more accurate communication
Who should take the test	<p><i>"you can do the swab test between 1-5 days post exposure."</i><sup>34</sup></p> <p>This is likely to be too early for the PCR molecular virus test specified to be sufficiently sensitive. Median time between exposure and symptom onset is around 5 days, so this proposed timing is likely pre-symptomatic when sensitivity is lower.</p>	<p><i>"Ideally samples should be taken from symptomatic individuals between days 1-5 from symptom onset. However, there are many cases when virus can be detected later into the illness."</i><sup>20</sup></p> <p>It would also be helpful to communicate that taking the test too early or late when it is less accurate may result in the test missing COVID-19 when it is present.</p>
Test accuracy	<p><i>"This test offers 99.9% reliability"</i><sup>29</sup></p> <p><i>"What is the accuracy of the test? 99.9%"</i><sup>29</sup></p> <p>It is unclear what the terms 'accuracy' or 'reliability' mean.</p>	<p>No website provided a full explanation of accuracy, we suggest our own example as follows</p> <p><i>"Test accuracy: The tests are sometimes inaccurate. If you have a negative result (you have not got antibodies to covid-19) then the test is very likely to be correct. If you get a positive result (you have got antibodies to covid-19) then the result is less accurate. Of the people who test positive, 92 in 100 do actually have COVID-19. Of the people who test negative, more than 99 in 100 do not have COVID -19. Here is more detail on the science: Test accuracy was measured in an independent evaluation of 158 people with COVID-19 and 364 people without COVID-19].<sup>54</sup> The test had sensitivity 98% and specificity 99.2%. That means that if 1000 people are tested, and 100 of those have COVID-19, then 98 of the 100 people with COVID-19 will be detected and 2 will be missed (test negative). Of the 900 people who don't have COVID-19, 892 will test negative, and 8 will test positive (and believe they have COVID-19 when they do not)."</i><sup>54</sup></p>
Interpreting test results of molecular virus tests	<p><i>"This highly accurate test will give you peace of mind that you can't infect others. This test is relevant when people who have been isolating wish to return to their household, community or workplace and need to know that they aren't infectious"</i><sup>16</sup></p> <p>This refers to the PCR molecular virus test, which is known to have low sensitivity so people testing negative may still be infected and infectious to others.</p> <p>Reasons for taking the PCR test cited as <i>"You need to know if you are</i></p>	<p><i>"If you have tested positive for COVID-19, self-isolation is recommended so that you do not pass the virus to others...If your results are negative and you're having symptoms, continue to follow isolation precautions and ask your healthcare provider if you need further testing."</i><sup>35</sup></p> <p>Linking information on the low negative predictive value of the PCR test to recommendations to continue self-isolation may strengthen the message.</p>

	<i>infectious or not” and “You want to let your household members know if they need to self-isolate”<sup>25</sup></i>	
Interpreting test results of antibody tests	<p><i>“A positive test result indicates that you have been exposed to Covid-19 and your immune system has produced antibodies in response to the virus. If you have had no symptoms for at least 7 days, you should have some level of immunity to Covid-19 and may not be able to transmit the virus to others or become infected by it again.”<sup>19</sup></i></p> <p>We do not currently know whether presence of antibodies infers immunity.</p>	<p><i>“There is still a great deal about Covid-19 immunity that we do not yet fully understand... If your IgG test is positive it means you have had Covid-19 exposure sufficiently to make an antibody response to the virus. There is currently no scientific evidence confirming if the presence of antibodies correlates to immunity or how long the antibodies will last for.”<sup>21</sup></i></p>

**Table 1:** Predefined information items which we would expect to be communicated to a person considering purchasing a test for COVID-19, and misinformation items which we would consider inappropriate to communicate, with rationale.

Information item	Rationale
<b>Who should take the test</b>	
1. Does the website clearly explain whether it is a test for antibodies (whether you have previously had the disease) or active virus (whether you have it now)?	To help the potential purchaser select the most appropriate test type.
2. Does the website explain when to test?	Accuracy is heavily dependent on timing. Antibody tests undertaken too early have low sensitivity (they make false negative errors i.e. miss cases of COVID-19). Molecular virus tests undertaken very early or too late have reduced sensitivity.
<b>Test accuracy information</b>	
3. Can you identify the test which is used? i.e. the manufacturer	There has been significant media coverage of the accuracy of different manufacturers' tests. Providing this information enables those interested to find out more.
4. Does the website give accuracy to detect cases? (sensitivity)	An informed potential purchaser would want to ensure tests successfully identify COVID-19.
5. Does the website give accuracy to detect non-cases? (specificity)	An informed potential purchaser would want to ensure tests did not misidentify COVID-19.
6. Does the website state how many samples the accuracy claims are based upon?	Accuracy data based on few samples is less reliable. Whilst few people may be interested in the detail of the test accuracy study design, number of samples/patients may be of interest.
7. Does the website give information on post-test probability of having or ruling out the disease? (Positive predictive value or negative predictive value at any prevalence)	This is the most important accuracy information for a person considering buying a test. For an individual whose molecular virus test result is positive, the positive predictive value gives them the probability that they currently have COVID-19. For an individual whose molecular virus test is negative, the negative predictive value is the probability that they do not currently have COVID-19. For an individual whose antibody test is positive, the positive predictive value is the probability that they have COVID-19 antibodies. For an individual whose antibody test is negative the negative predictive value is the probability that they do not have COVID-19 antibodies. These metrics are dependent on disease prevalence as well as sensitivity and specificity, but can reasonably be calculated with informed estimates of prevalence.
8. Does the website give a link or reference to a journal article of test accuracy?	Indicating the source of these data would help substantiate the claims, and allow interested people to find out more.
<b>Avoiding misinformation about interpreting the test</b>	
9. Molecular virus test - does the website avoid the inaccurate statement that if you test negative you are not infectious or do not need to self-isolate?	The molecular virus tests are not very sensitive and so negative results may be false negatives, so the individual may still have the virus and be contagious.
10. Antibody test – does the website avoid the inaccurate statement that we know that test positive infers	A positive antibody test could be a false positive, meaning the individual does not have antibodies. Even if it is a true positive we do not know whether the presence of antibodies infers immunity,

immunity or allows you to put yourself at greater risk of virus exposure?	and how that changes over time as antibody levels drop.
Providing accurate information about interpreting the test	
11. Molecular virus test – does the website state that if you test positive you should self-isolate?	Individuals who test positive on a molecular virus test are likely to have active virus, and are likely to be contagious.
12. Molecular virus test – does the website state that if you test negative you may still have the disease?	Same rationale as item 9 above, but here we assessed whether the websites gave correct information (in addition to avoiding misinformation).
13. Antibody test – does the website explain that we do not know whether a positive test infers immunity, and/or that you shouldn't put yourself at more risk of exposure if you test positive?	Same rationale as item 10 above, but here we assessed whether the websites gave correct information (in addition to avoiding misinformation).

**Table 2:** Claims of test accuracy from websites (selected verbatim) and evidence identified from the manufacturers' Instructions for Use sheet (IFU), published papers and pre-prints.

Website information			Published information		
What do they say about accuracy?	Sensitivity (%)	Specificity (%)	Study details	Sensitivity (%)	Specificity (%)
<b>Abbott's Antibody test (Abbott Architect SARS-CoV-2 IgG)</b>					
<p><b>London Medical Laboratory<sup>33</sup></b>  <b>Sensitivity:</b> This test has proven to be 100% accurate in identifying antibodies to SARS-CoV-2 coronavirus at 14 days after onset of covid-19 symptoms.  <b>Specificity:</b> It is 99.63% specific. Or put another way, only 0.37% of over 1000 people tested who could not have been exposed to SARS-CoV-2 showed a false positive result.</p>	<b>100 (n=88)</b>	<b>99.63 (n=1070)</b>	<p><b>Manufacturer's clinical performance of test<sup>41</sup></b></p> <ul style="list-style-type: none"> <li><b>Positive samples tested:</b> 122 serum and plasma specimens were collected at different times from 31 subjects who tested positive for SARS-CoV-2 by a polymerase chain reaction (PCR) method and who also presented with COVID-19 symptoms.</li> <li><b>Negative samples tested:</b> 1,070 specimens, 997 specimens were collected prior to September 2019 (pre-COVID-19 outbreak). An additional 73 specimens were collected in 2020 from subjects who were exhibiting signs of respiratory illness but tested negative for SARS-CoV-2 by a PCR method (unclear how many participants)</li> <li><b>Reference standard:</b> PCR method</li> </ul>	<b>100 (n=88)</b>	<b>99.63 (n=1070)</b>
<p><b>MyHealthcare Clinic<sup>29</sup></b>  The manufacturer of the Antibody test (Abbott Laboratories) reports that an independent clinical performance evaluation of the test performed in the United Kingdom confirmed the following accuracy levels: <b>Sensitivity</b> (ability to identify positive cases) of 99.7%. <b>Specificity</b> (ability to identify negative cases) of 100%.</p>	<b>99.7 (n=NR)</b>	<b>100 (n=NR)</b>	<p><b>Bryan et al 2020<sup>55</sup></b></p> <ul style="list-style-type: none"> <li><b>Positive samples tested:</b> 125 patients who tested RT-PCR positive for SARS-CoV-2 for which 689 excess serum specimens were available (unclear how many at each time point).</li> <li><b>Negative samples tested:</b> 1,020 serum specimens collected prior to SARS-CoV-2 circulation in the United States</li> <li><b>Reference standard:</b> PCR method and pre-COVID-19 samples</li> </ul>	53.1 (at 7 days) (n=NR) 82.4 (at 10 days) (n=NR) 96.9 (at 14 days) (n=NR) <b>100.0 (at 17 days—data driven choice) (n=NR)</b>	<b>99.9 (n=1020)</b>
<p><b>The Online Clinic (Online Clinic (UK) Limited)<sup>26</sup></b>  Tests have a <b>sensitivity</b> of 100%. When using a patient-collected sample with one of our home sampling kits, the sensitivity of this test has been shown to reduce slightly to 97.5. Recent studies suggest a <b>specificity</b> of 99.9% and 99.8% respectively.</p>	<b>97.5-100 (n=NR)</b>	<b>99.8-99.9 (n=NR)</b>	<p><b>Phipps et al 2020<sup>56</sup></b></p> <ul style="list-style-type: none"> <li><b>Positive samples tested:</b> Only six patients with samples 14 days post symptom onset, the point at which the highest sensitivity was recorded. 173 suspected COVID-19 cases with 76 were confirmed positive by PCR methods.</li> <li><b>Negative samples tested:</b> Plasma samples from healthy donors (2019 blood donations and 2020 blood donations from healthy donors without recent illness)</li> <li><b>Reference standard:</b> PCR method for suspected COVID-19 cases to confirm positives; for negatives apparent healthy donors</li> </ul>	38 (all days) (n=76) 7 (<3 days) (n=15) 30 (3-7 days) (n=27) 33 (5-15 days) (n=15) <b>83 (after 14 days) (n=6)</b>	<b>100 (n=656)</b>
<p><b>At checks Limited<sup>31</sup></b>  Abbott claim their test is 100% <b>sensitive</b> (88 Samples) and 99.6% <b>specific</b> (1070 Samples).</p>	<b>98.5 (n=132)</b> <b>100</b>	<b>99.5 (n=186)</b>	<p><b>Public Health England (PHE) evaluation of the Abbott antibody test<sup>57</sup></b></p> <ul style="list-style-type: none"> <li><b>Positive samples tested:</b> 96 samples defined by a positive PCR from a swab sample for that patient</li> </ul>	<b>92.7 (all days) (n=96)</b> 93.4 (≥14 days)	<b>100 (n=759)</b>



<p>Our UK Accredited Partner Lab have run their own internal verification of these claims and achieved a <b>sensitivity</b> of 98.5% (132 Samples) and a <b>specificity</b> of 99.5%. (186 Samples).</p>	(n=88)	99.6 (n=1070)	<ul style="list-style-type: none"> <li>• <b>Negative samples tested:</b> 759 negative samples were included in the evaluation (351 samples that are rheumatoid factor, CMV, EBV or VZV positive; 11 seasonal coronavirus positive samples and 395 historic samples, 2 samples unclear). These samples have been chosen based on their collection before mid-2019 to ensure they are SARS-CoV-2 antibody negative, but will contain samples containing antibodies to other seasonal coronaviruses to provide an additional screen for the assay</li> <li>• <b>Reference standard:</b> PCR method and pre-COVID-19 samples</li> </ul>	(n=82) 93.9 (≥21 days) (n=76)	
<b>Epitope Diagnostics inc. (EDI) Antibody test (EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit)</b>					
<p><b>Summerfield Healthcare<sup>16</sup></b> We have a trusted product which is <b>specific</b> to COVID-19 and <b>sensitive</b>. As with all of these kits they undergo regular testing to ensure <b>accuracy</b> and <b>reliability</b> which on the last occasion were <b>100% accurate for both positive and negative samples</b>. Antibody test is very specific for COVID-19 (some inferior tests can mistake other infections for COVID-19 and wrongly reassure you); it is also very sensitive for the specific IgG antibody.</p>	NR (n=NR)	NR (n=NR)	<p><b>Manufacturer's clinical performance of test<sup>58</sup></b></p> <ul style="list-style-type: none"> <li>• <b>Positive samples tested:</b> RT-PCR confirmed positive patients.</li> <li>• <b>Negative samples tested:</b> Normal healthy patients with samples collected prior to the COVID-19 outbreak.</li> <li>• <b>Reference standard:</b> PCR method and pre-COVID-19 samples</li> </ul> <p><b>Krüttgen et al 2020<sup>59</sup></b></p> <ul style="list-style-type: none"> <li>• <b>Positive samples tested:</b> The sera of the 31 patients with positive SARS-CoV-2 PCR were collected 11.9 days (±5.0 days) post onset of symptoms. 22 sera were considered SARS-CoV-2 IgG positive (positive on at least two assays).</li> <li>• <b>Negative samples tested:</b> 53 sera were regarded as IgG negative</li> <li>• <b>Reference standard:</b> A serum was regarded as SARS-CoV-2 IgG negative if at least three of the four assays compared here (for the Euroimmun assay, the EDI assay, the Mikrogen assay, and the Viramed assay) had a negative test result applying the manufacturer's interpretation criteria. A serum was regarded as SARS-CoV-2 IgG positive if at least two of the four assays had a positive test result (comparator tests are also part of reference standard).</li> </ul>	98.4 (n=187)	99.8 (n=624)
<b>Randox PCR Antigen test (Randox Covid-19 Home Testing Kit)</b>					
<p><b>Randox<sup>23</sup></b> This is a PCR based test, utilising Randox Biochip Technology, to provide an <b>accurate diagnosis</b> for Covid-19.</p>	NR (n=NR)	NR (n=NR)	<p><b>Manufacturer's clinical performance of test<sup>42</sup></b></p> <ul style="list-style-type: none"> <li>• <b>Positive samples tested:</b> NR</li> <li>• <b>Negative samples tested:</b> NR</li> <li>• <b>Reference standard:</b> NR</li> </ul>	NR (n=NR)	NR (n=NR)

			<p><b>Public Health England (PHE) evaluation of the Randox antigen test<sup>60</sup></b></p> <ul style="list-style-type: none"> <li>• <b>Positive samples tested:</b> None</li> <li>• <b>Negative samples tested:</b> The assessment sample-panel totalled 195 specimens, including upper or lower respiratory clinical specimens negative for SARS-CoV-2 as determined by the validated in-house PHE PCR assay and dilutions of SARS-CoV-2</li> <li>• <b>Reference standard:</b> PHE PCR assay</li> </ul>	NR (n=0)	100 (n=195)
<p><b>Primerdesign Ltd Antigen test (Coronavirus (Covid-19) genesig Real-Time PCR assay)</b></p>					
<p><b>Rightangled Healthcare<sup>22</sup></b> Studies confirm Primerdesign COVID-19 assays are <b>highly specific</b> for the detection of SARS-CoV-2 virus and detection of coronavirus COVID-19 disease. Independent Clinical Performance Evaluation of Primerdesign COVID-19 assay by the National Infection Service, Public Health England, Colindale confirmed the <b>specificity</b> of this assay using upper or lower respiratory clinical samples from patients and known SARS-CoV-2 positive material. PHE confirmed the assay showed &gt;98% specificity to SARS-CoV-2 virus in clinical samples. An Independent Clinical Performance Evaluation by an NHS Clinical Pathology Laboratory using patient samples with respiratory symptoms confirmed the assay was 100% <b>specific</b> when tested against known positive and negative SARS-CoV-2 clinical samples.</p>	98 (n=50)	100 (n=50)	<p><b>Manufacturer's clinical performance of test<sup>43</sup></b></p> <ul style="list-style-type: none"> <li>• <b>Positive samples tested:</b> Contrived oropharyngeal swabs (50 positive)</li> <li>• <b>Negative samples tested:</b> Contrived oropharyngeal swabs (50 negative)</li> <li>• <b>Reference standard:</b> 50 swabs were contrived with SARS-CoV-2 whole viral genomic RNA</li> </ul> <p>100 (3x LoD) (n=7)</p> <p>100 (4-5x LoD) (n=5)</p> <p><b>van Kasteren et al 2020<sup>61</sup></b></p> <ul style="list-style-type: none"> <li>• <b>Positive samples tested:</b> Clinical samples previously submitted for routine SARS-CoV-2 diagnostics for which the presence of various amounts of SARS-CoV-2 RNA had been confirmed using in-house PCR.</li> <li>• <b>Negative samples tested:</b> Clinical samples with confirmed respiratory viruses (influenza virus type A (n=2), rhinovirus (n=2), RSV-A and -B)</li> <li>• <b>Reference standard:</b> SARS-CoV-2 RNA had been confirmed using in-house PCR</li> </ul> <p><b>Public Health England (PHE) evaluation of Primerdesign antigen test<sup>47</sup></b></p> <ul style="list-style-type: none"> <li>• <b>Positive samples tested:</b> None</li> <li>• <b>Negative samples tested:</b> : The assessment sample-panel totalled 195 specimens, including upper or lower respiratory clinical specimens negative for SARS-CoV-2 as determined by the validated in-house PHE PCR assay and dilutions of SARS-CoV-2</li> <li>• <b>Reference standard:</b> PHE PCR assay</li> </ul>	94.7 (1-2x LoD) (n=38)	100 (n=50)
				100 (3x LoD) (n=7)	
				100 (4-5x LoD) (n=5)	
				62.5 (n=16)	100 (n=6)
				NR (n=0)	100 (n=195)
<p><b>LabCorp Antigen test (COVID-19 RT-PCR test with Pixel by LabCorp™ COVID-19 test home collection kit)</b></p>					
<p><b>LabCorp<sup>35</sup></b> Customers provided with link to <b>FDA Emergency Use Authorization Summary</b>.</p>	100 (NP swabs) (n=40)	100 (NP swabs) (n=50)	<p><b>Manufacturer's clinical performance of test<sup>45</sup></b></p> <ul style="list-style-type: none"> <li>• <b>Positive samples tested:</b> Positive samples were comprised of 40 NP swabs and 40 BALs spiked with quantitated live SARS-CoV-2. 10 samples each were spiked at 8x, 4x, 2x, and 1X LoD.</li> <li>• <b>Negative samples tested:</b> Negative samples include 50 NP swabs and 50 BALs.</li> <li>• <b>Reference standard:</b> Contrived samples</li> </ul>	100 (NP swabs) (n=40)	100 (NP swabs) (n=50)
	100 (BALs) (n=40)	100 (BALs) (n=50)		100 (BALs) (n=40)	100 (BALs) (n=50)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

<b>Rutgers Clinical Genomics Antigen test (Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay)</b>						
<b>Hims<sup>36</sup></b> Customers provided with link to <b>FDA Emergency Use Authorization Summary.</b>	<b>100</b> <b>(n=30)</b>	<b>100</b> <b>(n=30)</b>		<b>Manufacturer's clinical performance of test<sup>44</sup></b> <ul style="list-style-type: none"> <li><b>Positive samples tested:</b> 30 contrived positive samples were tested</li> <li><b>Negative samples tested:</b> 30 contrived negative samples were tested</li> <li><b>Reference standard:</b> Contrived samples</li> </ul>	<b>100</b> <b>(n=30)</b>	<b>100</b> <b>(n=30)</b>

For peer review only

**Table 3:** Availability of finger-prick antibody tests post MHRA withdrawal from market notice (websites accessed on 11<sup>th</sup> to 12<sup>th</sup> June 2020)

Website	Status	Comments
PillDoctor <sup>32</sup>	Still available	<i>Test appears to still be available for purchase</i>
YourHealthFirst Clinic <sup>38</sup>	Still available	<i>Test appears to still be available for purchase</i>
Summerfield Healthcare <sup>16</sup>	Not currently available	<b>Webpage suggests finger-prick antibody test still available but not available in subsequent drop down menu.</b>
Doctorcall <sup>15</sup>	Not currently available	"Coming soon"  <b>Option on website to be notified when product is back in stock</b>
WebMed Pharmacy <sup>34</sup>	Not currently available	"Sorry the item you have selected is not currently available, please choose another option"  "Due to the high demand of orders, the Antibodies blood test service is currently not available."
Superdrug <sup>40</sup>	Not currently available	"We have temporarily halted the COVID-19 antibody testing service. If you have any questions please send us a message through your account."
Zava <sup>25</sup>	Out of stock	"This product is temporarily out of stock."  <b>Option on website to be notified when product is back in stock</b>
Better2Know <sup>19</sup>	Out of stock	"Currently out of stock"  <b>Website links to guidance from MHRA.</b>
Antibody Solutions <sup>28</sup>	Out of stock/ Modified test	"Please note: These kits are no longer in stock; however, we are offering a full blood sample collection service, either at your home or at one of our partner clinics."
Blue Horizon Medicals <sup>18</sup>	Modified test	"Ordering this test will allow us to send you a vacutainer kit, which allows a healthcare professional to draw a venous blood sample from your arm. You should only order this kit therefore if you have access to a healthcare professional with the appropriate skills. Phlebotomy should NOT be attempted by those who are unskilled."
Qured <sup>21</sup>	Modified test	"A healthcare professional will visit your home to take a venous blood sample."  "The antibody tests currently used by our laboratory are the Abbott test if you opt for venous blood collection by a healthcare professional, or the Siemens test if you opt to collect your blood sample yourself"  "These tests are currently validated for venous blood draw only, which is why our service includes an at-home blood draw from a healthcare professional. Home self-collection of blood using a finger prick kit for antibody testing has been temporarily paused pending evaluation by the Medicines and Healthcare Products Regulatory Agency (MHRA)."
CityDoc <sup>14</sup>	Modified test	"We are able to offer blood collection by the normal practice of intravenous blood sampling at our clinics across the UK and sent to our accredited UK laboratory for testing."
Atruchecks Limited <sup>31</sup>	Modified test	"PHE approved Abbott test in our accredited lab. Venous sample taken in central London clinic, off Harley street (W1)"
London Medical Laboratory <sup>33</sup>	Modified test	"This option is so you can arrange a home or workplace visit by a phlebotomist to take your blood for you."
The Online Clinic (Online Clinic (UK Limited) <sup>26</sup>	Suspended/ Modified test	"The self-collect home sampling service is currently suspended but will be back shortly. Please check back later."  "The Medicines and Healthcare Regulatory Agency is currently conducting a review of self-collect blood samples for this type of test and the service is unavailable until that review concludes. We now offer a home-sampling service where a phlebotomist attends your home (or other premises) to collect the blood sample from a vein. "
MyHealthcare Clinic <sup>29</sup>	Withdrawn/ Suspended	"We have unfortunately had to withdraw the PHE Approved Antibody Home Testing Kits, per the unexpected Government / MHRA ruling on 26 May re private testing. We do not currently have a date for when these Home Tests will be next available to private patients."
Medichecks <sup>37</sup>	Withdrawn/ Suspended	"Currently, the only way to get a private coronavirus antibody test is to buy a venous blood test where you will need to visit a nurse or health professional to have a sample collected from a vein in your arm. All private laboratories and private testing companies have paused self-collect finger-prick testing while the MHRA conducts its review."

		However, we are confident that this service will resume shortly once the laboratories have completed their validation studies.”
Babylon <sup>39</sup>	Withdrawn/ Suspended	<p>“Important update on COVID-19 Antibody Tests. The MHRA (the government regulator responsible for medicines and medical devices) has asked that all COVID-19 antibody testing from finger-prick blood samples be paused. The MHRA decision has impacted all testing of this type nationwide.”</p> <p>“The lab will not be offering further testing services until the MHRA have provided clearance to do so.”</p>

For peer review only

1  
2  
3 **Figure 1.** Proportion of home-sampling COVID-19 tests identified which met/did not meet each of  
4 the predefined criteria for clear communication.  
5

6 **Figure 2.** Recommendations given by websites on when to take the molecular virus tests and  
7 antibody tests. Test accuracy is dependent on correct timing.  
8  
9

### 10 **Author contributions**

11 All authors contributed to the conception of the work and interpretation of the findings. OO and JG  
12 performed the Google searches. STP, SB, KF, JG, OO, IMH, and MJP extracted the data. STP, AJS, MJP  
13 and CD undertook the analysis and drafted the manuscript. All authors critically revised the  
14 manuscript and approved the final version. STP acts as guarantor. The corresponding author attests  
15 that all listed authors meet authorship criteria and that no others meeting the criteria have been  
16 omitted.  
17  
18  
19  
20  
21  
22

### 23 **Funding statement**

24 This paper presents independent research supported by the NIHR Birmingham Biomedical Research  
25 Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of  
26 Birmingham. Dr Taylor-Phillips is supported by an NIHR Career Development Fellowship (CDF-2016-  
27 09-018). MS is supported by the National Institute for Health Research (NIHR) Applied Research  
28 Collaboration (ARC) West Midlands. The views expressed are those of the author(s) and not  
29 necessarily those of the NHS, the NIHR or the Department of Health and Social Care.  
30  
31  
32  
33  
34  
35  
36  
37

### 38 **Competing interests disclosed**

39 We have read and understood BMJ policy on declaration of interests and declare the following  
40 interests: STP is funded by the NIHR through a career development fellowship; KF is funded by the  
41 NIHR through a doctoral research fellowship; MS reports grants from NIHR Applied Research  
42 Collaboration WM; AJS, SB, MP, CD and JD report funding and support from NIHR Birmingham  
43 Biomedical Research Centre.  
44  
45  
46  
47  
48  
49

### 50 **Acknowledgement**

### 51 **License for publication**

52 I, Sian Taylor-Phillips, the Corresponding Author have the right to grant on behalf of all authors and  
53 do grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in  
54 perpetuity, in all forms, formats and media (whether known now or created in the future), to i)  
55 publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into  
56  
57  
58  
59  
60

1  
2  
3 other languages, create adaptations, reprints, include within collections and create summaries,  
4 extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the  
5 Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links  
6 from the Contribution to third party material where-ever it may be located; and, vi) licence any third  
7 party to do any or all of the above.  
8  
9  
10  
11  
12

### 13 **Ethical approval**

14 Ethical approval not required  
15  
16  
17

### 18 **Data sharing statement**


19 No additional data available  
20  
21  
22

### 23 **Transparency**

24 The lead authors and manuscript's guarantor affirms that the manuscript is an honest, accurate and  
25 transparent account of the study being reported; that no important aspects of the study have been  
26 omitted; and that any discrepancies from the study as planned have been explained.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




195x112mm (120 x 120 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



203x114mm (144 x 144 DPI)

**Supplementary Figure 1: Reported test manufacturer for the 41 tests for sale included in the cohort.**



\*7 of 13 'Not reported' antibody tests stated it was a finger prick test with no further detail.

View only

**Supplementary Table 1: Characteristics of included websites and COVID-19 tests**

Name of company	Type of company	Type of test	Name of test manufacturer	Home testing or home sampling	Regulatory approval CE/EUA or *endorsement
Superdrug <sup>40</sup>	Pharmacy	Antibody	Not Reported	Home sampling	-
CityDoc <sup>14</sup>	Private health clinic	Antibody	Not Reported	Home sampling	-
		Molecular	Not Reported	Home sampling	-
Rightangled Healthcare <sup>22</sup>	Online testing specialist	Molecular	Primerdesign Ltd	Home sampling	-
Randox <sup>23</sup>	Laboratory	Molecular	Randox PCR test	Home sampling	-
Samedaydoctor <sup>24</sup>	Private health clinic	Molecular	Not Reported	Home sampling	-
Zava <sup>25</sup>	Private health clinic	Antibody	Not Reported	Home sampling	CE
		Molecular	Not Reported	Home sampling	CE
The Online Clinic (Online Clinic (UK) Limited) <sup>26</sup>	Private health clinic	Antibody	Abbott Laboratories and Roche	Home sampling	-
		Molecular	Not Reported	Home sampling	CE
Doctorcall of Harley Street <sup>15</sup>	Private health clinic	Antibody	Not Reported	Home sampling	CE Endorse UK Government
		Molecular	Not Reported	Home sampling	CE
The Family Planning Association (FPA) <sup>27</sup>	Online sexual health specialist	Molecular	Not Reported	Home sampling	-
YourHealthFirst Clinic: Harley Street <sup>38</sup>	Private health clinic	Antibody	Not Reported	Home testing	CE
Antibody Solutions <sup>28</sup>	Company specialising in beauty treatments	Antibody	Not Reported	Home sampling	-
		Molecular	Not Reported	Home sampling	Endorse PHE, NHS
MyHealthcare Clinic <sup>29</sup>	Private health clinic	Antibody	Abbott	Home sampling	Endorse PHE
		Molecular	Not Reported	Home sampling	-
MedExpress <sup>30</sup>	Pharmacy	Molecular	Not Reported	Home sampling	-
Summerfield Healthcare <sup>16</sup>	Private health clinic	Antibody	Epitope Diagnostics inc (EDI)	Home sampling	-
		Molecular	Not Reported	Home sampling	-
Atruchecks Limited <sup>31</sup>	Online test supplier	Antibody	Abbott	Home sampling	Endorse PHE
		Molecular	Not Reported	Home sampling	-
PillDoctor <sup>32</sup>	Pharmacy	Antibody	Not Reported	Home sampling	-
	Pharmacy	Molecular	Not Reported	Home sampling	Endorse UK Government
London Medical Laboratory <sup>33</sup>	Laboratory	Antibody	Abbott	Home sampling	CE Endorse PHE
		Molecular	Not Reported	Home sampling	CE Endorse PHE
WebMed Pharmacy <sup>34</sup>	Pharmacy	Antibody	Not Reported	Home sampling	CE Endorse PHE
		Molecular	Not Reported	Home sampling	Endorse PHE


Name of company	Type of company	Type of test	Name of test manufacturer	Home testing or home sampling	Regulatory approval CE/EUA or *endorsement
Babylon <sup>39</sup>	Private health clinic	Antibody	Not Reported	Home sampling	-
Medichecks <sup>37</sup>	Online test specialist	Antibody	Not Reported	Home sampling	CE
LondonDoctorsClinic <sup>17</sup>	Private health clinic	Molecular	Not Reported	Home sampling	Endorse PHE, NHS, UK Government
Blue Horizon Medicals <sup>18</sup>	Online test specialists	Antibody	Not Reported	Home sampling	Endorse PHE
		Molecular	Not Reported	Home sampling	-
better2know <sup>19</sup>	Online sexual health specialist	Antibody	Not Reported	Home sampling	CE
		Molecular	Not Reported	Home sampling	-
Private Harley Street Clinic <sup>20</sup>	Private health clinic	Molecular	Not Reported	Home sampling	Endorse PHE
Qured <sup>21</sup>	Private health clinic	Antibody	Not Reported	Home sampling	CE Endorse PHE
		Molecular	Not Reported	Home sampling	CE
LabCorp <sup>35</sup>	Laboratory	Molecular	LabCorp (139900)	Home sampling	EUA
Hims Inc <sup>36</sup>	Private health clinic	Molecular	Rutgers Clinical Genomics Laboratory	Home sampling	EUA

\* Statement that the test is 'used by', 'approved by' or 'compliant with'.

Abbreviations: PHE, Public Health England; EUA, Emergency Use Authorisation

**Supplementary Figure 1: Reported test manufacturer for the 41 tests for sale included in the cohort.**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



\*7 of 13 'Not reported' antibody tests stated it was a finger prick test with no further detail.

Peer review only

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4
Bias	9	Describe any efforts to address potential sources of bias	4
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	N/A
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	N/A
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	5
		(b) Give reasons for non-participation at each stage	n/a
		(c) Consider use of a flow diagram	N/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	5
		(b) Indicate number of participants with missing data for each variable of interest	5
Outcome data	15*	Report numbers of outcome events or summary measures	5-8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make	n/a



		clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	7
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	n/a
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	7
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	7,8
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	8
Generalisability	21	Discuss the generalisability (external validity) of the study results	8
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Funding statement

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Information given by websites selling home self-sampling COVID-19 tests: An analysis of accuracy and completeness

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-042453.R1
Article Type:	Original research
Date Submitted by the Author:	23-Sep-2020
Complete List of Authors:	Taylor-Phillips, Sian; University of Warwick, Warwick Medical School Berhane, Sarah; University of Birmingham, Institute of Applied Health Research Sitch, Alice; University of Birmingham, Public Health, Epidemiology and Biostatistics Freeman, Karoline; University of Warwick, Division of Health Sciences, Warwick Medical School Price, Malcolm; University of Birmingham, Institute of Applied Health Research Davenport, Clare; University of Birmingham, Epidemiology, Public Health and Biostatistics Geppert, Julia; University of Warwick, Warwick Medical School Harris, Isobel; University of Birmingham Osokogu, Osemeke; University of Warwick, Warwick Medical School Skrybant, Magdalena; University of Birmingham Deeks, Jonathan; University of Birmingham, Institute of Applied Health Research
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Communication, Evidence based practice, Health policy, Public health
Keywords:	Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Public health < INFECTIOUS DISEASES, PUBLIC HEALTH, INFECTIOUS DISEASES, COVID-19

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Information given by websites selling home self-sampling COVID-19 tests: An analysis of accuracy**  
4 **and completeness**  
5

6 Taylor-Phillips S (0000-0002-1841-4346), Berhane S (0000-0002-1437-0411), Sitch AJ (0000-0001-  
7 7727-4497), Freeman K (0000-0002-9963-2918), Price MJ (0000-0002-7352-3027), Davenport C  
8 (0000-0001-5659-4889), Geppert J (0000-0001-6446-6094), Harris IM (0000-0001-8125-3832),  
9 Osokogu O, Skrybant M (0000-0001-7119-2482), Deeks JJ (0000-0002-8850-1971)

10  
11 Taylor-Phillips S, Professor of Population Health, Test Evaluation Research Group, Institute of Applied Health  
12 Research, University of Birmingham, Birmingham, UK and Warwick Medical School, University of Warwick,  
13 Coventry, UK

14  
15 Berhane S, Medical Statistician, Test Evaluation Research Group, Test Evaluation Research Group, Institute of  
16 Applied Health Research, University of Birmingham, Birmingham, UK and NIHR Birmingham Biomedical  
17 Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham,  
18 Birmingham, UK

19  
20 Sitch AJ, Senior Lecturer in Biostatistics, Test Evaluation Research Group, Institute of Applied Health Research,  
21 University of Birmingham, Birmingham, UK and NIHR Birmingham Biomedical Research Centre, University  
22 Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK

23  
24 Freeman K, Research Fellow, Institute of Applied Health Research, University of Birmingham, Birmingham, UK,  
25 and Warwick Medical School, University of Warwick, Coventry, UK

26  
27 Price MJ, Lecturer in Biostatistics, Test Evaluation Research Group, Institute of Applied Health Research,  
28 University of Birmingham, Birmingham, UK and NIHR Birmingham Biomedical Research Centre, University  
29 Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK

30  
31 Davenport C, Senior Clinical Lecturer, Test Evaluation Research Group, Institute of Applied Health Research,  
32 University of Birmingham, Birmingham, UK and NIHR Birmingham Biomedical Research Centre, University  
33 Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK

34  
35 Geppert J, Research Fellow, Warwick Medical School, University of Warwick, Coventry, UK

36  
37 Harris IM, Research Fellow, Test Evaluation Research Group, Institute of Applied Health Research, University of  
38 Birmingham, Birmingham, UK

39  
40 Osokogu O, Research Fellow, Warwick Medical School, University of Warwick, Coventry, UK

41  
42 Skrybant M, Public Involvement and Engagement Lead and Public Contributor, Institute of Applied Health  
43 Research, University of Birmingham, Birmingham, UK and NIHR Applied Research Collaboration West Midlands

44  
45 Deeks JJ, Professor of Biostatistics, Test Evaluation Research Group, Institute of Applied Health Research,  
46 University of Birmingham, Birmingham, UK and NIHR Birmingham Biomedical Research Centre, University  
47 Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK

48  
49  
50  
51 Correspondence to: Sian Taylor-Phillips [s.taylor-phillips@warwick.ac.uk](mailto:s.taylor-phillips@warwick.ac.uk)

52  
53 Warwick Medical School  
54 University of Warwick  
55 Coventry  
56 CV4 7AL

57  
58  
59 Word count: 4344  
60

## ABSTRACT

**Objectives:** To assess the accuracy and completeness of information provided by websites selling home self-sampling and testing kits for COVID-19.

**Design:** Cross-sectional observational study.

**Setting:** All websites (n=27) selling direct to user home self-sampling and testing for COVID-19 (41 tests) in the UK (39 tests) and US (2 tests) identified by a website search on 23<sup>rd</sup> May 2020.

**Main outcome measures** — Thirteen predefined basic information items to communicate to a user, including who should be tested, when and how testing should be done, test accuracy, and interpretation of results.

**Results:** Many websites did not provide the name or manufacturer of the test (32/41; 78%), when to use the test (10/41; 24%), test accuracy (12/41; 29%), and how to interpret results (21/41; 51%). Sensitivity and specificity were the most commonly reported test accuracy measures (either reported for 27/41 (66%) tests); we could only link these figures to manufacturers' documents or publications for four (10%) tests. Predictive values, most relevant to users, were rarely reported (five [12%] tests reported positive predictive values). For molecular virus tests, 9/23 (39%) websites explained that test positives should self-isolate, and 8/23 (35%) explained that test negatives may still have the disease. For antibody tests, 12/18 (67%) websites explained that testing positive does not necessarily infer immunity from future infection. Seven (39%) websites selling antibody tests claimed the test had a CE mark, when they were for a different intended use (venous blood rather than finger-prick samples).

**Conclusions:** At the point of online purchase of home self-sampling COVID-19 tests, users in the UK are provided with incomplete, and in some cases misleading information on test accuracy, intended use and test interpretation. Best practice guidance for communication about tests to the public should be developed and enforced for online sales of COVID-19 tests.

### Strengths and Weaknesses

- We believe this is the first research on accuracy of information provided by websites selling tests for COVID-19, where users may put themselves or others at increased risk of transmission if results are misinterpreted.
- We duplicated processes of searching and data extraction to minimise bias
- Using pre-specified criteria, we found evidence that websites selling home self-sampling COVID-19 tests provided incomplete and inaccurate information on test accuracy and interpretation of test results at the point of purchase.
- We developed basic guidance on what should be communicated when selling tests, including the type of test; situations when the test should be used; the time when the test should be done and details of how it should be done; the name of the test and details from clinical accuracy studies; evidence of compliance with regulatory approvals; explanation of test results using accessible and relevant metrics such as predictive values; and guidance to the interpretation and actions based on results.
- We only included websites from the UK and US, so whilst the principles of what should be communicated apply to all countries, the results about data completeness are not generalisable beyond the UK and US.

## INTRODUCTION

The 2019 novel coronavirus (COVID-19) pandemic has resulted in national population measures such as restricted movement ('lockdown'), and mass testing programmes. Testing is regarded as critical to manage the pandemic - the two main test types available being molecular virus tests (to detect current infection) and antibody tests (to detect previous infection). The World Health Organization (WHO) recommends polymerase chain reaction (PCR)-based molecular virus testing of symptomatic individuals to detect current COVID-19 infection,<sup>1</sup> to enable identification and isolation of confirmed cases, and tracing of those exposed for further testing. However, due to the sensitivity for a single PCR test being as low as 70%,<sup>2</sup> the WHO states that even two consecutive negative PCR tests do not rule out infection with COVID-19.<sup>1</sup> Antibody tests are not recommended for individual use by the WHO, because we do not yet understand whether presence of antibodies infers immunity from future infection. Their sensitivity has been estimated at around 80-90%, thus there is also a risk of false negatives.<sup>3</sup> Timing of testing is critical for both tests: molecular tests are thought to be most accurate when used within five days of the onset of symptoms,<sup>4</sup> antibody tests are most accurate two or more weeks after onset of symptoms.<sup>3</sup>

There are now multiple websites selling both molecular virus tests and antibody tests outside of national testing programmes. To ensure appropriate use, interpretation and actions following testing, it is necessary for tests to be sold with clear communication about who should use each test, when and how samples should be taken, and the implications of positive and negative results. Previous research investigating direct to user sales of genetic testing found that the information provided was incomplete, particularly the implications of test results and limitations of testing, and was not always in an accessible and understandable format.<sup>5-7</sup>

Direct to user sale of tests are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK and the Food and Drug Administration (FDA) in the US. Europe<sup>8</sup> and the USA<sup>9</sup> operate a risk based regulation for in vitro diagnostic devices (IVDs) which depends on the intended use of the test and indications for use. IVDs for *home testing* fall into higher risk categories reflecting the fact they are initiated, performed and interpreted without professional guidance and require evidence that lay users correctly use the test and understand test results. Lay user studies are required as the basis for the instructions for use (IFU) document for the IVD.<sup>10</sup> *Home sampling* tests are different from *home testing* as they receive approval based on home collected specimens with the test analysis being undertaken by professionals. At the time of writing, there were no COVID-19 antibody tests with a CE mark for either home sampling or home testing<sup>11</sup> (the two COVID-19 antibody tests purchased by the UK Government are approved for use in venous but not finger-prick blood samples) whilst several molecular virus tests have regulatory approval for home *sampling* and are being used in the UK track and trace programme.<sup>12</sup> Most websites selling COVID-19 tests would be classified by the MHRA as 'distributors', which gives clear obligations to supply the information provided by manufacturers with the test, but no specific guidance around communication on the website at the point of sale. Such claims are covered by the Advertising Standards Agency. In the US, there are no COVID-19 antibody tests with regulatory approval for home *testing* but four molecular (PCR) virus tests that have approval for home *sampling*<sup>13</sup> where the appropriateness of the test purchase is assessed by a professional either pre-purchase or following a purchase request.

We analysed the information given to individuals considering purchasing a molecular virus or antibody COVID-19 test online for home self-sampling. We chose to review tests for sale in both the UK and US to cover two different regulatory systems with contrasting health services. We recorded information regarding who should be tested and when, claims about test accuracy, and information

1  
2  
3 about how to interpret results. As the MHRA instigated a withdrawal of sales of antibody tests based  
4 on finger-prick blood samples on May 29<sup>th</sup> 2020 where tests require venous blood samples,<sup>11</sup> we also  
5 evaluated how test vendors have responded.  
6

## 7 **METHODS**

8  
9 Our research question was how complete, accurate and informative is the information that online  
10 websites selling home self-sampling and testing for COVID-19 provide to the public?  
11

### 12 **Identification of websites**

13 The search was designed to identify a representative sample of websites and online advertisements  
14 which would be seen by an individual searching for a non-specific COVID-19 test. We aimed to  
15 identify websites selling home self-sampling and testing for COVID-19 using molecular virus and/or  
16 antibody tests directly to users. Two researchers performed the searches independently on the  
17 same day (23<sup>rd</sup> May 2020) using the Google search engine in incognito mode in Google Chrome, with  
18 geo-locations for the UK and for the USA. In order to emulate a simple search for a non-specific  
19 coronavirus test, the search terms were (coronavirus OR covid-19 OR covid19) AND (test OR testing  
20 OR kit). Two researchers independently screened all results against the inclusion criteria,  
21 disagreements were resolved by a third researcher. For the UK search, we included websites moved  
22 to the top of the search results through advertisements, in order to mirror what a user would have  
23 seen on that day.  
24  
25

### 26 **Inclusion criteria**

27  
28 We included websites selling molecular virus and/or antibody tests for COVID-19 direct to users in  
29 either the US or UK. We included point-of-care and laboratory-based tests, with the proviso that the  
30 sample was taken at home by the individual themselves. We excluded tests with assisted sampling  
31 (e.g. drive-through testing), or where part of the testing process before purchase included video,  
32 telephone or in-person contact with a medical professional (as we could not objectively assess the  
33 information content of such interactions). We included websites selling tests both via direct  
34 purchase and insurance funding, but excluded local or national government websites providing tests  
35 (including Public Health England [PHE] and the UK National Health Service [NHS]), and websites  
36 providing tests as part of a research study. We included all eligible tests, including where a single  
37 website sold multiple eligible tests. We excluded websites with a minimum order of more than a  
38 single test, as these targeted suppliers rather than individual users.  
39  
40

### 41 **Data extraction**

42 We extracted information about the test manufacturer and type of test; when testing was  
43 recommended; claims made about test accuracy; the advice given about changing behaviour in light  
44 of test results; accreditation; and the test cost. We assessed the information provided against a  
45 predefined list of items which we would expect to be communicated to a person considering  
46 purchasing a test for COVID-19, detailed in Table 1.  
47

48 We extracted claims made about regulatory approval of the tests, in particular CE-IVD approval in  
49 the UK and FDA approval in the US, and where possible compared claims to the actual approval  
50 status for the test. We also extracted claims made about approval from non-regulatory bodies such  
51 as PHE and the NHS.  
52

53 Website contents were extracted between 23<sup>rd</sup> and 28<sup>th</sup> May 2020. One researcher extracted data  
54 from each website onto a predefined data extraction form, and downloaded the website as an  
55 image file. A second researcher checked each extraction using the pdf copy to exclude temporal  
56 changes.  
57

### 58 **Patient and public involvement**



A public contributor (MS), with both experience of being involved in research and leading public involvement in research, provided input into this project. MS has an interest in communicating scientific information to lay audiences. The rapid timeframes in which the research was conducted limited the scope for more comprehensive public involvement. MS contributed to discussions, paper drafts and is included as a co-author.

Ethics approval was not required for this review of publicly available documents.

## RESULTS

For the UK our Google searches retrieved 550 results, and for the US they retrieved 430 results. After the first round of sifting by 2 reviewers 46 potentially eligible websites were identified. Of these 19 websites were later excluded, 13 of which only sold in quantities greater than one or to laboratories/hospitals/workplaces, 5 who incorporated contact with a health professional before the sale, and one which was withdrawn from sale between the search and extraction. We identified 23 molecular virus testing services<sup>14-36</sup> and 18 antibody testing services<sup>14-16 18 19 21 25 26 28 29 31-34 37-40</sup> meeting the inclusion criteria, sold via 27 websites (25 from the UK<sup>14-34 37-40</sup> and 2 from the US<sup>35 36</sup>). One website<sup>40</sup> did not appear in the main search, but was mentioned in many UK news articles, so was included in the cohort. Only two websites using home sampling were identified in the US, the first and second to be approved by the FDA for this use.<sup>35 36</sup> Basic characteristics of the websites and tests are given in Supplementary Table 1.

The websites consisted of 13 private health clinics,<sup>14-17 20 21 24-26 29 36 38 39</sup> four pharmacies,<sup>30 32 34 40</sup> four suppliers of a range of direct to consumer testing online,<sup>18 22 31 37</sup> three laboratories,<sup>23 33 35</sup> two online sexual health specialists<sup>19 27</sup> and one supplier of beauty treatments.<sup>28</sup> All 23 molecular virus tests were laboratory-based tests with home sampling. Of the 18 antibody tests, 17 were laboratory-based tests with home self-sampling, and one was a point-of-care test.<sup>38</sup> The test manufacturer was identifiable for 9/41 (22%) tests, further details are provided in Supplementary Figure 1.

The mean cost of molecular virus testing was £168 (range £65 to £279) in the UK and \$135 (range \$119 to \$150) in the US. The mean cost of antibody tests was £87 (range £55 to £130) in the UK.

The proportion of websites which met each of the criteria for clear communication (outlined in Table 1) is shown in Figure 1, and examples of reporting are given in Box 1.

### Explaining which test and when to test

All 27 websites stated whether the 41 tests for sale were molecular virus tests or antibody tests, of which 40/41 described the test clearly. Guidance on timing of taking the molecular virus tests and the antibody tests was provided by 15/23 (65%)<sup>15 17-21 25-27 29-31 34-36</sup> and 16/18 (89%)<sup>15 16 18 19 21 25 26 28 29 31 33 34 37-40</sup> websites, respectively. Recommendations on timing and variation in timing of sampling are detailed in Figure 2, with several contrary to current advice or opinion.<sup>4</sup>

### Test accuracy and interpretation

Of the 41 tests for sale, the websites reported a measure of test accuracy (sensitivity, specificity, positive or negative predictive value) for 27 (66%) tests: 16/18 (89%) for antibody tests<sup>14 15 18 19 21 25 26 28 29 31 33 34 37-40</sup> and 11/23 (48%) for molecular tests.<sup>14 17 20-22 25 26 33-36</sup> An additional 10/41 (24%) tests (two antibody<sup>16 32</sup> and eight molecular tests<sup>15 16 18 19 23 27 29 32</sup>) only reported test performance using unclear terms such as 'accuracy' or 'reliability', for example "This test has a 99.9% accuracy"<sup>19</sup> and "This test offers 99.9% reliability".<sup>29</sup> Tests with unclear performance values may be referring to analytical performance, such as "Our test is sensitive to fewer than 100 copies of the target viral RNA, making it a highly accurate test."<sup>32</sup> For two (5%) molecular tests, no text or values referring to accuracy were reported on the websites.<sup>24 31</sup>

Sensitivity and specificity were the most commonly reported accuracy measures, provided for 27/41 (66%)<sup>14 15 17-22 25 26 28 29 31 33-40</sup> and 22/41 (54%)<sup>15 17 19-22 25 26 28 29 31 33-37 39 40</sup> tests, respectively. Sensitivity estimates ranged from 95% to 100% for antibody tests (n=16)<sup>14 15 18 19 21 25 26 28 29 31 33 34 37-40</sup> and 97.5% to 100% for molecular tests (n=11)<sup>14 17 20-22 25 26 33-36</sup>; specificity estimates ranged from 97.5% to 100% for antibody tests (n=13)<sup>15 19 21 25 26 28 29 31 33 34 37 39 40</sup> and were reported as 100% for all molecular tests (n=9).<sup>17 20-22 25 26 34-36</sup> Five of the 41 tests (13%; two antibody tests<sup>28 31</sup> and three molecular<sup>14 20 33</sup> tests) provided an estimate or statements of sensitivity and/or specificity under conditions of perfect use rather than pragmatic use, for example *“If there are any coronavirus on your swab it will definitely find it”*.<sup>33</sup>

No websites directly referred to positive predictive values (PPV), but they were indirectly reported for 5/41 (12%) tests.<sup>25 25 21 20 40</sup> Two antibody<sup>25 40</sup> and three molecular tests<sup>25 21 20</sup> made a statement about the lack of false positives (implying a PPV of 100%), for example *“if it shows a positive result, it can only be for COVID-19”*.<sup>25</sup> No cross-reactivity (meaning the test would not identify other viruses, only COVID-19 virus) was referred to by websites for 13/41 (32%) tests (five antibody<sup>16 25 33 34 40</sup> and eight molecular tests<sup>17 20-22 25 26 28 34</sup>). Negative predictive value (NPV) was not referred to by any websites; however, statements implying that the NPV was less than 100% were given for 4/41 (10%) available tests (two antibody<sup>25 31</sup> and two molecular tests<sup>20 35</sup>), for example *“The test can sometimes show a negative result even if you are infected SARS-CoV-2, the virus that causes COVID-19”*.<sup>35</sup>

The number of samples used to generate accuracy data were given for 5/41 (12%) tests; two antibody tests<sup>31 33</sup> and three molecular tests.<sup>22 35 36</sup> Accuracy data were linked to a journal publication for only 1/41 (2%) test.<sup>33</sup>

Information on interpreting both positive and negative molecular virus test results was presented for 4/23 (17%) websites.<sup>20 33-35</sup> Twelve of the 18 (67%) websites selling antibody tests informed potential customers prior to purchase that a positive antibody test may not infer immunity from future infection<sup>14 16 18 21 25 28 32-34 37 39 40</sup> (Figure 1).

Where tests could be identified, we checked accuracy claims against data from published papers, pre-prints (based on information obtained from searches from ongoing Cochrane reviews for these tests) and manufacturer’s data in the Instructions for Use (IFU) sheet for each test (Table 2). Four websites reported clinical performance data for the Abbott IgG antibody test: two<sup>31 33</sup> quoted the performance figures from the IFU<sup>41</sup>, for the other two<sup>26 29</sup> no exact match with available studies could be made. Of the four molecular tests, no performance data were available for the Randox test<sup>23</sup> (including in the IFU<sup>42</sup>), no direct match of clinical performance results could be made for the website selling the Primerdesign genesig PCR assay<sup>22</sup> (where the IFU only reported data from contrived samples<sup>43</sup>), whereas the data reported by US websites<sup>35 36</sup> selling the LabCorp and Rutgers PCR tests, respectively, matched data from the manufacturers’ IFUs.<sup>44 45</sup>

### Claims about Regulatory Approval and Endorsement

Across the 25 UK websites, there were 17 antibody tests for home sampling,<sup>14-16 18 19 21 25 26 28 29 31-34 37 39 40</sup> one antibody test for home testing<sup>38</sup> and 21 molecular tests for home sampling<sup>14-34</sup> for sale. There was no mention of regulatory approval or endorsement for 18/39 (46%) tests, seven antibody tests<sup>14 16 26 28 32 39 40</sup> and 11 molecular tests<sup>14 16 18 19 22-24 27 29-31</sup> (see Supplementary Table 1).

For home sampling antibody tests, 7/17 (41%) included a statement that the test had a CE mark<sup>15 19 21 25 33 34 37</sup> and 7/17 (41%) websites included a clear statement that the test had endorsement from a policy making body such as Public Health England, the NHS or the UK or other European government.<sup>15 18 21 29 31 33 34</sup> This is despite the fact that currently no COVID-19 antibody tests have regulatory approval for home sampling or home testing. Claims being made about home sampling tests were based on approved test use by health professionals using venous rather than finger-prick samples:

1  
2  
3 *"All of our home test kits are CE-marked. This is one of the two IgG tests approved by the*  
4 *Government for UK use."*<sup>15</sup>  
5  
6

7 One website<sup>38</sup> claimed it had regulatory approval for its home *testing* antibody test:

9 *"Our test has been accepted by Medicines and Healthcare products regulatory Agency (MHRA),*  
10 *which means that it can be applied across the EU including UK. We confirm our product can meet the*  
11 *requirement of In vitro Diagnostic Medical Devices Directive (98/79EC) and standards complying with*  
12 *CE Declaration of Conformity."*<sup>38</sup>  
13

14 Five of 21 (24%) UK websites selling molecular virus tests for home sampling included a statement  
15 that they had regulatory approval<sup>15 21 25 26 33</sup> and 6 (29%) websites<sup>17 20 28 32-34</sup> claimed approval from a  
16 policy making body for this intended use. The manufacturer or name of the molecular tests for  
17 which websites were claiming regulatory approval or endorsement could not be identified. Only for  
18 two websites selling molecular tests<sup>22 23</sup>, the test manufacturer could be identified, neither of which  
19 made any claims about regulation or endorsement. One of these tests<sup>23</sup> is mentioned by the UK  
20 government as part of its COVID-19 testing strategy<sup>46</sup> and the other<sup>22</sup> was one of the tests which was  
21 independently evaluated by PHE.<sup>47</sup>  
22

23 Both USA websites selling molecular viral tests<sup>35 36</sup> have approval from the FDA for home sampling  
24 during the COVID-19 pandemic. These websites included information about the eligibility checks that  
25 purchasers would need to undergo either prior to purchase or prior to test processing.  
26

27 We reviewed the 18 UK websites selling home COVID-19 antibody tests<sup>14-16 18 19 21 25 26 28 29 31-34 37-40</sup> on  
28 11<sup>th</sup>/12<sup>th</sup> June 2020 after the MHRA had instructed sales of these tests to cease because of the lack  
29 of approval for the tests using finger-pick samples.<sup>11</sup> We found two websites<sup>32 38</sup> that appeared to  
30 still be selling finger-prick tests, four<sup>14 21 28 31</sup> had switched to providing a venous blood sampling  
31 service, two<sup>18 33</sup> required the purchaser to find their own phlebotomist to draw a blood sample to  
32 send, six<sup>15 16 19 25 34 40</sup> simply stated that tests were out of stock and were unavailable, whilst four<sup>26 29</sup>  
33 <sup>37 39</sup> reported the MHRA guidance and indicated that they had suspended sales (Table 3).  
34  
35  
36  
37  
38

## 39 **DISCUSSION**

40 We identified 27 websites selling COVID-19 tests direct to the public, 25 in the UK but only two in  
41 the US, which may be explained by the FDA stipulations requiring clinician involvement in the testing  
42 process. We observed that many websites failed to provide complete information on the name and  
43 manufacturer of the test (no information for 32/41 tests), when to use the test (no information for  
44 10/41 tests), the accuracy of the test (no information for 12/41 tests), and how to interpret results  
45 (no information for 21/41 tests), which will hinder the public making informed choices about testing,  
46 using tests correctly and understanding what test results mean. Without adequate and correct  
47 information the public may purchase the wrong or a poor test, or use the test in the wrong way or at  
48 the wrong point in time. These errors or application will increase their chances of getting an  
49 erroneous test result. Even when used properly, few websites assisted users in interpreting test  
50 results and understanding their inherent uncertainty.  
51

52 This rapid evaluation was designed to provide timely results in the context of a fast-moving global  
53 pandemic. The search was not designed to be exhaustive, rather to represent what a person typing  
54 "coronavirus test" or similar into a Google search would have retrieved. Using different phrases such  
55 as "coronavirus antibody test" would have identified additional websites, but there is no reason to  
56  
57  
58  
59  
60

1  
2  
3 suspect that they would be different from those summarised here. The timing of the search and data  
4 extraction will have affected results. Data extraction was shortly before the UK MHRA clarified that  
5 antibody tests were not approved for finger-prick samples, only for venous samples. The search only  
6 identified two US websites selling tests with home sample collection, but at the point of going to  
7 press eight tests are now approved on the FDA website.<sup>48</sup> The criteria that we used to assess  
8 completeness of communication (detailed in Table 1) were defined *a priori*, but due to time  
9 constraints a formal process for developing these was not followed. However, all key elements of  
10 the search, selection and data extraction processes were undertaken independently by two  
11 researchers, reducing the possibility of errors. We only assessed information provided prior to  
12 purchase, as complete information should be given at this stage to inform the purchasing decision.  
13 However, further information would have been given after purchase, for example within the  
14 instructions for use, which was beyond the scope of this paper.

15  
16  
17  
18 The issues we have identified are examples of poor and misleading practice, and some merit further  
19 investigation by the MHRA and Advertising Standards Authority. At the time of going to press two  
20 antibody tests remained on sale and we have reported these to the MHRA. The communication of  
21 test accuracy appears to contravene advertising standards in the UK. The five websites that reported  
22 PPV of 100% contrary to the wider evidence base, and all websites making accuracy claims which is  
23 not linked to supporting evidence appear to contravene section 12.1 of the ASA code,<sup>49</sup> which states  
24 that objective claims must be backed by evidence. Further, websites provided specificity and  
25 sensitivity, or general claims of ‘accuracy’ rather than positive and negative predictive values  
26 explained in lay terms, and the ASA have previously ruled against this practice as misleading in the  
27 case of non-invasive prenatal testing for trisomies.<sup>50</sup> Finally, the lack of complete information on the  
28 implications of positive and negative test results does not appear to be covered by any UK  
29 regulation, perhaps because the ASA 12.2.1<sup>49</sup> prohibit diagnosis by post or email, and so this  
30 information is intended to be provided by contact with a healthcare professional. Whilst such  
31 contact with a health professional is happening in the US it does not appear to be in the UK.  
32 Regulation of product labelling provides a means to oversee information communicated for self-  
33 testing products bought in person, but there is currently no equivalent for online testing services in  
34 the UK. This gap in regulation could be solved by expanding the responsibility of the MHRA to  
35 include communication by ‘distributors’ at the point of online purchase, working collaboratively with  
36 the Advertising Standards Agency. There was a large variation in price of testing in the UK, and in  
37 many cases these differences do not appear to be justified by differences in the service provided.  
38 Greater regulation and standardisation of website claims may reduce this price differential by  
39 making comparisons between websites easier, and removing unsubstantiated claims.

#### 45 Key Communication Requirements

46  
47 It is important that all test users are given adequate and appropriate information to help them make  
48 safe and informed choices. We identified five key communication issues with websites selling direct  
49 to consumer home-sampling COVID-19 tests. All five of these issues may be improved by developing  
50 a basic framework of what information should be provided, and standard ways to present such  
51 information. This would also facilitate comparison between websites.

##### 52 53 54 1) *The type of test and the questions which it can help address.*

55  
56 It is essential that companies selling tests identify the type of test, and the situations in which it is  
57 appropriate to order such a test. Whilst websites were clear whether they were selling molecular or  
58 antibody tests, they also need to indicate the situations when it is appropriate to order a molecular  
59 “swab” test or an antibody “blood” test in order to select the correct one. The two US websites  
60

1  
2  
3 utilised questionnaires recording symptoms and exposure which were reviewed by clinicians prior to  
4 tests being despatched which provides a more rigorous check on whether the test request is  
5 sensible.  
6

7  
8 *2) How and when the test should be used.*

9 Both molecular and antibody tests need to be used at different time points in the disease course.  
10 The sensitivity of both types of tests will fall if used at the wrong time point (sensitivity of 31% for  
11 antibody tests in the first week since onset of symptoms<sup>3</sup>), substantially increasing the risks of  
12 infection or antibody response being undetected. Recommended time points when samples should  
13 be taken were absent for 10/39 UK tests (26%). Some timing statements were misleading,  
14 suggesting using the test at time points which are known to be too early or too late. Some websites  
15 stated dates based on time since exposure, others since symptom onset which is median 5 days after  
16 exposure. Both are required to be able to advise both asymptomatic patients and patients with  
17 unknown exposure when they should order and use the tests.  
18  
19

20  
21 Websites must also describe the full testing process and clearly indicate what is required of users to  
22 complete testing. For example, two antibody websites currently indicate that purchasers will need  
23 to identify individuals qualified to take venous blood samples, which is impractical for most people.  
24

25 *3) The test name, evidence of its accuracy, and evidence of its regulatory approval for the*  
26 *purpose to which it is put.*  
27

28 The majority of tests were for sale by third parties, ranging from healthcare providers to beauty  
29 treatment specialists. In most cases (32/41; 78%) it was not possible to identify the test being used  
30 or the manufacturer. This does not allow the individual to know the product that they are buying,  
31 and precludes the opportunity for the user to verify its regulatory status and the claims being made.  
32

33 Information on test accuracy was absent or uninterpretable for 12/41 (29%) tests. Numerical  
34 accuracy claims could only be matched to published evidence for 4/41 (10%) of tests. In these  
35 instances, figures most closely matched those from the manufacturers' Instructions for Use leaflets,  
36 which tended to report the highest observed values of sensitivity and specificity, and were based on  
37 studies more akin to analytic validity than clinical validity evaluations. Accuracy measures from  
38 analytic validity studies should not be assumed to give a good representation of test accuracy when  
39 applied in practice to the public. A wide range of terms were used, several of which did not have a  
40 clear meaning. It appeared that test accuracy data is not available at all for some tests (Randox)<sup>42</sup>, or  
41 only based on contrived samples (Primerdesign)<sup>43</sup> and not on real patients. For molecular COVID-19  
42 tests, no clinical performance data were available that were based on self-sampled swab tests.  
43 Withholding the fact that there is no patient based evidence of the accuracy of these tests from the  
44 public is unacceptable. It is important that the reported accuracy is based on all reviewed evidence  
45 and not selected results, and clearly explains how applicable the evidence is to the public.  
46  
47

48 Naming tests is essential to be able to check their regulatory status. Seven of 18 (39%) UK websites  
49 selling antibody tests inappropriately claimed CE marking, when the CE marking was for a different  
50 intended use (venous rather than finger-prick blood samples). Antibody tests are not approved for  
51 home use in the US, and none were found in our search. The UK regulator acted after we had  
52 reviewed UK websites, clarifying that antibody tests which are approved for the use with venous  
53 samples should not be sold for the use with finger-prick samples. However, 2/18 remain available for  
54 online sale at the point of going to press (accessed 11<sup>th</sup> to 12<sup>th</sup> June 2020). The molecular tests we  
55 could identify are approved for home sampling, however, the name and manufacturer was not  
56 identifiable for most websites.  
57  
58  
59  
60



#### 4) *What test results mean.*

Research concerning the communication of test accuracy evidence is limited and is largely restricted to self-selected, professional and postgraduate student groups.<sup>51</sup> Communication of test accuracy evidence is complex for several reasons. Research has highlighted the importance of communicating the potential consequences of positive and negative test results (use of predictive values) and the importance of contextualising estimates of accuracy with reference to a healthcare setting (for example hospital in patient, hospital outpatient, community).<sup>52 53</sup> Presenting test accuracy as frequencies rather than as probabilities improves understanding.

To interpret results, test users need to know how to interpret positive and negative test results (predictive values), not the proportion of cases detected (sensitivity) and non-cases correctly diagnosed (specificity). Positive predictive value was only reported for 5/41 (12%) tests, and in all five they claimed it was 100% which is inconsistent with the broader evidence base. Negative predictive value was not reported at all.

Most websites gave insufficient information regarding interpreting test results. Only 8/23 (35%) websites explained that a negative molecular virus test does not rule out COVID-19, and only 12/18 (67%) explained that a positive antibody test does not necessarily infer immunity from future COVID-19 infection or transmission.

#### 5) *Decisions which could be made based on the test results.*

Misunderstanding of the implications of test results could mean that individuals put themselves or others at risk of infection in the mistaken belief that they do not have COVID-19, or that they are immune to COVID-19. This last category probably has the greatest potential for harm. Clear communication about the meaning of test results as detailed above should be linked to evidence-based guidance about behaviour modification in light of test results. We found widespread evidence of websites failing to provide such evidence-based guidance, and some cases of websites actively suggesting unsafe behaviour.

## CONCLUSIONS

At the point of online purchase of home self-sampling COVID-19 tests, users in the UK are provided with incomplete, and in some cases misleading information on test application, accuracy and interpretation. Many websites omit trustworthy guidance on the timing of tests, the interpretation of positive and negative test results, and the implications of results. Best practice guidance for communication about tests to the public should be developed and the role of the regulator in enforcing complete and accurate information should be reviewed. This should be underpinned by robust collaborative qualitative research exploring how members of the public interpret information and measures of accuracy, thus informing how it can be provided in a way that is clear, complete and accessible

## References

1. World Health Organization. Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: interim guidance, 19 March 2020. Geneva: World Health Organization, 2020.
2. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, et al. FALSE-NEGATIVE RESULTS OF INITIAL RT-PCR ASSAYS FOR COVID-19: A SYSTEMATIC REVIEW. *medRxiv* 2020:2020.04.16.20066787. doi: 10.1101/2020.04.16.20066787
3. Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. *Cochrane Database of Systematic Reviews* 2020(6)

- 1  
2  
3 4. National Health Service (NHS). Ask for an antigen test to check if you have coronavirus now  
4 [updated 17 June 2020. Available from: <https://www.nhs.uk/conditions/coronavirus-covid-19/testing-and-tracing/ask-for-a-test-to-check-if-you-have-coronavirus/> accessed  
5 19/06/2020.  
6  
7
- 8 5. Covolo L, Rubinelli S, Ceretti E, et al. Internet-Based Direct-to-Consumer Genetic Testing: A  
9 Systematic Review. *J Med Internet Res* 2015;17(12):e279. doi: 10.2196/jmir.4378 [published  
10 Online First: 2015/12/19]
- 11 6. De S, Pietila AM, Iso-Touru T, et al. Information Provided to Consumers about Direct-to-Consumer  
12 Nutrigenetic Testing. *Public Health Genomics* 2019;22(5-6):162-73. doi: 10.1159/000503977  
13 [published Online First: 2019/11/30]
- 14 7. Singleton A, Erby LH, Foisie KV, et al. Informed choice in direct-to-consumer genetic testing  
15 (DTCGT) websites: a content analysis of benefits, risks, and limitations. *J Genet Couns*  
16 2012;21(3):433-9. doi: 10.1007/s10897-011-9474-6 [published Online First: 2011/12/24]
- 17 8. The European Parliament and the Council of the European Union. REGULATION (EU) 2017/746 OF  
18 THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017 on in vitro diagnostic  
19 medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU  
20 2017 [Available from: [https://eur-lex.europa.eu/legal-  
21 content/EN/TXT/HTML/?uri=CELEX:32017R0746&from=EN#d1e4364-176-1](https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32017R0746&from=EN#d1e4364-176-1) accessed  
22 30/05/2020.  
23
- 24 9. U.S. Food & Drug Administration. Federal Food, Drug and Cosmetic Act (FD&C Act) Chapter V:  
25 Drugs and Devices 2018 [Available from: [https://www.fda.gov/regulatory-  
26 information/federal-food-drug-and-cosmetic-act-fdc-act/fdc-act-chapter-v-drugs-and-  
27 devices](https://www.fda.gov/regulatory-information/federal-food-drug-and-cosmetic-act-fdc-act/fdc-act-chapter-v-drugs-and-devices) accessed 30/05/2020.  
28
- 29 10. Medicines & Healthcare products Regulatory Agency. Guidance for notified bodies on the  
30 regulation of IVDs for self-testing 2012.  
31 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment-  
32 data/file/377885/Guidance\\_for\\_notified\\_bodies\\_on\\_the\\_regulation\\_of\\_IVDs\\_for\\_self-  
33 testing.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/377885/Guidance_for_notified_bodies_on_the_regulation_of_IVDs_for_self-testing.pdf) (accessed 02/06/2020).  
34
- 35 11. Medicine & Healthcare products Regulatory Agency. Guidance For industry and manufacturers:  
36 COVID-19 tests and testing kits. Updated 29 May 2020 [Available from:  
37 [https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-  
38 covid-19-work/for-industry-and-manufactures-covid-19-tests-and-testing-kits](https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work/for-industry-and-manufactures-covid-19-tests-and-testing-kits) accessed  
39 30/05/2020.
- 40 12. Medicine & Healthcare products Regulatory Agency. Guidance For patients, the public and  
41 professional users: a guide to COVID-19 tests and testing kits. [Available from:  
42 [https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-  
43 covid-19-work/for-patients-the-public-and-professional-users-a-guide-to-covid-19-tests-and-  
44 testing-kits](https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work/for-patients-the-public-and-professional-users-a-guide-to-covid-19-tests-and-testing-kits) accessed 04/06/2020.  
45
- 46 13. U.S. Food & Drug Administration. Emergency Use Authorizations [updated 06/04/2020.  
47 Available from: [https://www.fda.gov/medical-devices/emergency-situations-medical-  
48 devices/emergency-use-authorizations#covid19ivd](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd) accessed 30/05/2020.
- 49 14. CityDoc. Coronavirus Home Testing Kits [Available from: [https://www.citydoc.org.uk/covid-19-  
50 home-testing-kit/](https://www.citydoc.org.uk/covid-19-home-testing-kit/) accessed 25/05/2020.
- 51 15. DoctorCall. Covid-19 Home Testing Kits [Available from: [https://www.doctorcall.co.uk/private-  
52 gp-services/coronavirus--covid-19--testing](https://www.doctorcall.co.uk/private-gp-services/coronavirus--covid-19--testing) accessed 24/05/2020 and 26/05/2020.
- 53 16. Summerfield Healthcare. Covid-19 Test kits and Covid-19 Test Antibody kits [Available from:  
54 <https://www.summerfieldhealthcare.co.uk/corona-virus-testing/> accessed 24/05/2020.
- 55 17. London Doctors Clinic. Services - Private Coronavirus Test [Available from:  
56 <https://www.londondoctorsclinic.co.uk/services/private-coronavirus-test/> accessed  
57 25/05/2020.  
58  
59  
60



18. Blue Horizon Medicals. COVID-19 Home Coronavirus Test Kits [Available from: <https://bluehorizonbloodtests.co.uk/collections/covid-19-coronavirus-tests> accessed 24/05/2020.
19. Better2Know. Covid-19 testing [Available from: <https://www.better2know.co.uk/page/covid-19> accessed 26/05/2020.
20. Private Harley Street Clinic. COVID-19 PCR Home Sample Kit - Currently infected [Available from: <https://privateharleystreetclinic.com/products/covid-19-test> accessed 24/05/2020.
21. Qured. Covid-19 PCR and Antibody Tests Now Available [Available from: <https://qured.com/covid-19-testing/> accessed 24/05/2020 and 25/05/2020.
22. Rightangled. COVID-19 Test [Available from: <https://rightangled.co/product/covid-19-test> accessed 24/05/2020.
23. Randox Health. COVID-19 Home Testing Kit [Available from: <https://www.randoxhealth.com/product/coronavirus-covid-19-home-testing-kit/> accessed 26/05/2020.
24. SameDayDoctor. COVID-19 Abbott Coronavirus testing [Available from: <https://samedaydoctor.org/service/covid-19-coronavirus-antibody-testing/> accessed 24/05/2020.
25. Zava. Coronavirus antibody and swab testing service [Available from: <https://www.zavamed.com/uk/coronavirus-service.html> accessed 22/05/2020.
26. TheOnlineClinic. Coronavirus (COVID-19) [Available from: <https://www.theonlineclinic.co.uk/coronavirus-testing.asp> accessed 27/05/2020.
27. Family Planning Association (FPA). Covid-19 Coronavirus Home Test Kit [Available from: <https://www.fpa.org.uk/product/new-covid-19-coronavirus-home-test-kit> accessed 26/05/2020.
28. Antibody Solutions. Covid-19 Home IgG Sample Collection Test Kit and Lab Test [Available from: <https://antibodyolutions.co.uk/> accessed 27/05/2020.
29. MyHealthcare Clinic. Coronavirus (COVID-19) Testing [Available from: <https://myhealthcareclinic.com/covid-19-purchase-tests/> accessed 24/05/2020.
30. MedExpress Enterprises Ltd. Coronavirus Testing - Home Sample Collection Kit [Available from: <https://www.medexpress.co.uk/testing/covid19/coronavirus-covid19-home-testing-kit-pcr> accessed 24/05/2020.
31. Atruchecks Ltd. Covid-19 tests - Private Covid-19 Clinical Testing Service [Available from: <https://www.atruchecks.com/category/covid-19-tests> accessed 27/05/2020.
32. PillDoctor. Covid-19 [Available from: <https://www.pilldoctor.co.uk/product-category/Covid-19> accessed 27/05/2020.
33. London Medical Laboratory. Coronavirus Antibody & PCR Tests - In Stock Now [Available from: <https://www.privatecoronavirustests.com/> accessed 24/05/2020.
34. Webmed Pharmacy Ltd. covid-19 tests [Available from: <https://webmedpharmacy.co.uk/buy/covid19testkit> accessed 23/05/2020.
35. Pixel by LabCorp. COVID-19 Test (At-Home Kit) [Available from: <https://www.pixel.labcorp.com/at-home-test-kits/covid-19-test> accessed 27/05/2020.
36. Hims Inc. COVID-19 Saliva Test [Available from: <https://www.forhims.com/covid-test> accessed 28/05/2020.
37. Medichecks.com Ltd. Coronavirus Antibody Blood Test [Available from: <https://medichecks.com/pages/coronavirus-antibody-blood-test-information> accessed 23/05/2020.
38. YourHealthFirst Clinic. Ten minute coronavirus self-testing kit [Available from: <https://www.yourhealthfirst.uk/our-services/covid-19-rapid-test/> accessed 25/05/2020.
39. Babylon. COVID-19 Antibody Test [Available from: <https://www.babylonhealth.com/coronavirus/covid-19-antibody-test> accessed 23/05/2020.

- 1
- 2
- 3
- 4 40. Superdrug. Coronavirus Antibody Test Service [Available from:  
5 <https://onlinedoctor.superdrug.com/coronavirus-antibody-test.html> accessed 28/05/2020.
- 6 41. Abbott Laboratories. SARS-CoV-2 IgG ARCHITECT. *Instructions for Use (IFU)* April 2020.  
7 <https://www.fda.gov/media/137383/download>.
- 8 42. Randox Laboratories Ltd. Extended Coronavirus Multiplex Array EV4418 User Manual.  
9 <https://static1.squarespace.com/static/568969badf40f3987cccc1d9/t/5e6912a5d041d92494d4fdc7/1583944358498/EV4418.doc.pdf>.
- 10 43. Primerdesign Ltd. Coronavirus (COVID-19) genesig® Real-Time PCR assay - For Emergency Use  
11 Authorization Only - Instructions for Use (IFU) Issue 1.02. 31 March 2020.  
12 <https://www.fda.gov/media/136309/download>.
- 13 44. U.S. Food & Drug Administration. ACCELERATED EMERGENCY USE AUTHORIZATION (EUA)  
14 SUMMARY - SARS-CoV-2 ASSAY (Rutgers Clinical Genomics Laboratory). 2020.  
15 <https://www.fda.gov/media/137776/download>.
- 16 45. U.S. Food & Drug Administration. ACCELERATED EMERGENCY USE AUTHORIZATION (EUA)  
17 SUMMARY - COVID-19 RT-PCR TEST(LABORATORY CORPORATION OF AMERICA). 2020.  
18 <https://www.fda.gov/media/136151/download>.
- 19 46. Department of Health & Social Care. Coronavirus (COVID-19) - Scaling up our testing  
20 programmes. Department of Health and Social Care. Published 04 April 2020.  
21 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/878121/coronavirus-covid-19-testing-strategy.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/878121/coronavirus-covid-19-testing-strategy.pdf) (accessed 11/06/2020).
- 22 47. National Infection Service (NIS) laboratories Public Health England. Rapid assessment of the  
23 Novacyt Primerdesign Coronavirus (COVID-19) genesig® Real-Time PCR assay. June 2020.  
24 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/889330/Rapid\\_assessment\\_Novacyt\\_Primerdesign\\_Coronavirus\\_COVID-19\\_Genesig.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/889330/Rapid_assessment_Novacyt_Primerdesign_Coronavirus_COVID-19_Genesig.pdf).
- 25 48. U.S. Food & Drug Administration. In Vitro Diagnostics EUAs: U.S. Food & Drug Administration;  
26 2020 [updated 18/06/2020. Available from: <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas> accessed 19/06/2020.
- 27 49. The Advertising Standards Authority Ltd. (ASA) and The Committee of Advertising Practice Ltd.  
28 (CAP). 12 Medicines, medical devices, health-related products and beauty products - CAP  
29 Code. 2020 [Available from:  
30 [https://www.asa.org.uk/type/non\\_broadcast/code\\_section/12.html](https://www.asa.org.uk/type/non_broadcast/code_section/12.html) accessed 20/06/2020.
- 31 50. The Advertising Standards Authority Ltd. (ASA) and The Committee of Advertising Practice Ltd.  
32 (CAP). Non-Invasive Prenatal Testing (NIPT) – A look at the ASA’s rulings. CAP News. 16 Jan  
33 2020 [Available from: <https://www.asa.org.uk/news/non-invasive-prenatal-testing-nipt-a-look-at-the-asa-s-rulings.html> accessed 20/06/2020.
- 34 51. Whiting PF, Davenport C, Jameson C, et al. How well do health professionals interpret diagnostic  
35 information? A systematic review. *BMJ Open* 2015;5(7):e008155. doi: 10.1136/bmjopen-2015-008155 [published Online First: 2015/07/30]
- 36 52. Whiting P, Leeflang M, de Salis I, et al. Guidance was developed on how to write a plain language  
37 summary for diagnostic test accuracy reviews. *J Clin Epidemiol* 2018;103:112-19. doi:  
38 10.1016/j.jclinepi.2018.07.008 [published Online First: 2018/07/24]
- 39 53. Whiting P, Davenport C. Understanding test accuracy research: a test consequence graphic.  
40 *Diagn Progn Res* 2018;2:2. doi: 10.1186/s41512-017-0023-0 [published Online First:  
41 2018/02/01]
- 42 54. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19)  
43 From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med*  
44 2020;172(9):577-82. doi: 10.7326/M20-0504 [published Online First: 2020/03/10]
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1  
2  
3 55. Bryan A, Pepper G, Wener MH, et al. Performance Characteristics of the Abbott Architect SARS-  
4 CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. *J Clin Microbiol* 2020 doi:  
5 10.1128/JCM.00941-20 [published Online First: 2020/05/10]  
6  
7 56. Phipps WS, SoRelle JA, Li Q-Z, et al. SARS-CoV-2 Antibody responses do not predict COVID-19  
8 disease severity. *medRxiv* 2020:2020.05.15.20103580. doi: 10.1101/2020.05.15.20103580  
9  
10 57. Public Health England. Evaluation of the Abbott SARS-CoV-2 IgG for the detection of anti-SARS-  
11 CoV-2 antibodies. Version of 8 June 2020. London, 2020:1-18.  
12  
13 58. Epitope Diagnostics Inc. EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit (KT-1032). *Instructions*  
14 *for Use (IFU)* May 2020. <http://www.epitopediagnostics.com/covid-19-elisa>.  
15  
16 59. Kruttgen A, Cornelissen CG, Dreher M, et al. Comparison of four new commercial serologic  
17 assays for determination of SARS-CoV-2 IgG. *J Clin Virol* 2020;128:104394. doi:  
18 10.1016/j.jcv.2020.104394 [published Online First: 2020/05/18]  
19  
20 60. Public Health England. Rapid assessment of the Randox Extended Coronavirus Multiplex Array  
21 assay. V01.20 ed. London, June 2020:1-5.  
22  
23 61. van Kasteren PB, van der Veer B, van den Brink S, et al. Comparison of seven commercial RT-PCR  
24 diagnostic kits for COVID-19. *J Clin Virol* 2020;128:104412. doi: 10.1016/j.jcv.2020.104412  
25 [published Online First: 2020/05/18]  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Box 1: Examples of clear/accurate and unclear/potentially misleading website content

Information item	Example of unclear/potentially misleading information	Example of clearer and more accurate communication
Who should take the test	<p><i>"you can do the swab test between 1-5 days post exposure."</i><sup>34</sup></p> <p>This is likely to be too early for the PCR molecular virus test specified to be sufficiently sensitive. Median time between exposure and symptom onset is around 5 days, so this proposed timing is likely pre-symptomatic when sensitivity is lower.</p>	<p><i>"Ideally samples should be taken from symptomatic individuals between days 1-5 from symptom onset. However, there are many cases when virus can be detected later into the illness."</i><sup>20</sup></p> <p>It would also be helpful to communicate that taking the test too early or late when it is less accurate may result in the test missing COVID-19 when it is present.</p>
Test accuracy	<p><i>"This test offers 99.9% reliability"</i><sup>29</sup></p> <p><i>"What is the accuracy of the test? 99.9%"</i><sup>29</sup></p> <p>It is unclear what the terms 'accuracy' or 'reliability' mean.</p>	<p>No website provided a full explanation of accuracy, we suggest our own example as follows</p> <p><i>"Test accuracy: The tests are sometimes inaccurate. If you have a negative result (you have not got antibodies to covid-19) then the test is very likely to be correct. If you get a positive result (you have got antibodies to covid-19) then the result is less accurate. Of the people who test positive, 92 in 100 do actually have COVID-19. Of the people who test negative, more than 99 in 100 do not have COVID -19. Here is more detail on the science: Test accuracy was measured in an independent evaluation of 158 people with COVID-19 and 364 people without COVID-19].<sup>54</sup> The test had sensitivity 98% and specificity 99.2%. That means that if 1000 people are tested, and 100 of those have COVID-19, then 98 of the 100 people with COVID-19 will be detected and 2 will be missed (test negative). Of the 900 people who don't have COVID-19, 892 will test negative, and 8 will test positive (and believe they have COVID-19 when they do not)."</i><sup>54</sup></p>
Interpreting test results of molecular virus tests	<p><i>"This highly accurate test will give you peace of mind that you can't infect others. This test is relevant when people who have been isolating wish to return to their household, community or workplace and need to know that they aren't infectious"</i><sup>16</sup></p> <p>This refers to the PCR molecular virus test, which is known to have low sensitivity so people testing negative may still be infected and infectious to others.</p> <p>Reasons for taking the PCR test cited as <i>"You need to know if you are</i></p>	<p><i>"If you have tested positive for COVID-19, self-isolation is recommended so that you do not pass the virus to others...If your results are negative and you're having symptoms, continue to follow isolation precautions and ask your healthcare provider if you need further testing."</i><sup>35</sup></p> <p>Linking information on the low negative predictive value of the PCR test to recommendations to continue self-isolation may strengthen the message.</p>

	<i>infectious or not” and “You want to let your household members know if they need to self-isolate”<sup>25</sup></i>	
Interpreting test results of antibody tests	<p><i>“A positive test result indicates that you have been exposed to Covid-19 and your immune system has produced antibodies in response to the virus. If you have had no symptoms for at least 7 days, you should have some level of immunity to Covid-19 and may not be able to transmit the virus to others or become infected by it again.”<sup>19</sup></i></p> <p>We do not currently know whether presence of antibodies infers immunity.</p>	<p><i>“There is still a great deal about Covid-19 immunity that we do not yet fully understand... If your IgG test is positive it means you have had Covid-19 exposure sufficiently to make an antibody response to the virus. There is currently no scientific evidence confirming if the presence of antibodies correlates to immunity or how long the antibodies will last for.”<sup>21</sup></i></p>

**Table 1:** Predefined information items which we would expect to be communicated to a person considering purchasing a test for COVID-19, and misinformation items which we would consider inappropriate to communicate, with rationale.

Information item	Rationale
<b>Who should take the test</b>	
1. Does the website clearly explain whether it is a test for antibodies (whether you have previously had the disease) or active virus (whether you have it now)?	To help the potential purchaser select the most appropriate test type.
2. Does the website explain when to test?	Accuracy is heavily dependent on timing. Antibody tests undertaken too early have low sensitivity (they make false negative errors i.e. miss cases of COVID-19). Molecular virus tests undertaken very early or too late have reduced sensitivity.
<b>Test accuracy information</b>	
3. Can you identify the test which is used? i.e. the manufacturer	There has been significant media coverage of the accuracy of different manufacturers' tests. Providing this information enables those interested to find out more.
4. Does the website give accuracy to detect cases? (sensitivity)	An informed potential purchaser would want to ensure tests successfully identify COVID-19.
5. Does the website give accuracy to detect non-cases? (specificity)	An informed potential purchaser would want to ensure tests did not misidentify COVID-19.
6. Does the website state how many samples the accuracy claims are based upon?	Accuracy data based on few samples is less reliable. Whilst few people may be interested in the detail of the test accuracy study design, number of samples/patients may be of interest.
7. Does the website give information on post-test probability of having or ruling out the disease? (Positive predictive value or negative predictive value at any prevalence)	This is the most important accuracy information for a person considering buying a test. For an individual whose molecular virus test result is positive, the positive predictive value gives them the probability that they currently have COVID-19. For an individual whose molecular virus test is negative, the negative predictive value is the probability that they do not currently have COVID-19. For an individual whose antibody test is positive, the positive predictive value is the probability that they have COVID-19 antibodies. For an individual whose antibody test is negative the negative predictive value is the probability that they do not have COVID-19 antibodies. These metrics are dependent on disease prevalence as well as sensitivity and specificity, but can reasonably be calculated with informed estimates of prevalence.
8. Does the website give a link or reference to a journal article of test accuracy?	Indicating the source of these data would help substantiate the claims, and allow interested people to find out more.
<b>Avoiding misinformation about interpreting the test</b>	
9. Molecular virus test - does the website avoid the inaccurate statement that if you test negative you are not infectious or do not need to self-isolate?	The molecular virus tests are not very sensitive and so negative results may be false negatives, so the individual may still have the virus and be contagious.
10. Antibody test – does the website avoid the inaccurate statement that we know that test positive infers	A positive antibody test could be a false positive, meaning the individual does not have antibodies. Even if it is a true positive we do not know whether the presence of antibodies infers immunity,



immunity or allows you to put yourself at greater risk of virus exposure?	and how that changes over time as antibody levels drop.
Providing accurate information about interpreting the test	
11. Molecular virus test – does the website state that if you test positive you should self-isolate?	Individuals who test positive on a molecular virus test are likely to have active virus, and are likely to be contagious.
12. Molecular virus test – does the website state that if you test negative you may still have the disease?	Same rationale as item 9 above, but here we assessed whether the websites gave correct information (in addition to avoiding misinformation).
13. Antibody test – does the website explain that we do not know whether a positive test infers immunity, and/or that you shouldn't put yourself at more risk of exposure if you test positive?	Same rationale as item 10 above, but here we assessed whether the websites gave correct information (in addition to avoiding misinformation).



**Table 2:** Claims of test accuracy from websites (selected verbatim) and evidence identified from the manufacturers' Instructions for Use sheet (IFU), published papers and pre-prints.

Website information			Published information		
What do they say about accuracy?	Sensitivity (%)	Specificity (%)	Study details	Sensitivity (%)	Specificity (%)
<b>Abbott's Antibody test (Abbott Architect SARS-CoV-2 IgG)</b>					
<p><b>London Medical Laboratory<sup>33</sup></b>  <b>Sensitivity:</b> This test has proven to be 100% accurate in identifying antibodies to SARS-CoV-2 coronavirus at 14 days after onset of covid-19 symptoms.  <b>Specificity:</b> It is 99.63% specific. Or put another way, only 0.37% of over 1000 people tested who could not have been exposed to SARS-CoV-2 showed a false positive result.</p>	<b>100 (n=88)</b>	<b>99.63 (n=1070)</b>	<p><b>Manufacturer's clinical performance of test<sup>41</sup></b></p> <ul style="list-style-type: none"> <li><b>Positive samples tested:</b> 122 serum and plasma specimens were collected at different times from 31 subjects who tested positive for SARS-CoV-2 by a polymerase chain reaction (PCR) method and who also presented with COVID-19 symptoms.</li> <li><b>Negative samples tested:</b> 1,070 specimens, 997 specimens were collected prior to September 2019 (pre-COVID-19 outbreak). An additional 73 specimens were collected in 2020 from subjects who were exhibiting signs of respiratory illness but tested negative for SARS-CoV-2 by a PCR method (unclear how many participants)</li> <li><b>Reference standard:</b> PCR method</li> </ul>	<b>100 (n=88)</b>	<b>99.63 (n=1070)</b>
<p><b>MyHealthcare Clinic<sup>29</sup></b>  The manufacturer of the Antibody test (Abbott Laboratories) reports that an independent clinical performance evaluation of the test performed in the United Kingdom confirmed the following accuracy levels: <b>Sensitivity</b> (ability to identify positive cases) of 99.7%. <b>Specificity</b> (ability to identify negative cases) of 100%.</p>	<b>99.7 (n=NR)</b>	<b>100 (n=NR)</b>	<p><b>Bryan et al 2020<sup>55</sup></b></p> <ul style="list-style-type: none"> <li><b>Positive samples tested:</b> 125 patients who tested RT-PCR positive for SARS-CoV-2 for which 689 excess serum specimens were available (unclear how many at each time point).</li> <li><b>Negative samples tested:</b> 1,020 serum specimens collected prior to SARS-CoV-2 circulation in the United States</li> <li><b>Reference standard:</b> PCR method and pre-COVID-19 samples</li> </ul>	53.1 (at 7 days) (n=NR) 82.4 (at 10 days) (n=NR) 96.9 (at 14 days) (n=NR) <b>100.0 (at 17 days—data driven choice) (n=NR)</b>	<b>99.9 (n=1020)</b>
<p><b>The Online Clinic (Online Clinic (UK) Limited)<sup>26</sup></b>  Tests have a <b>sensitivity</b> of 100%. When using a patient-collected sample with one of our home sampling kits, the sensitivity of this test has been shown to reduce slightly to 97.5. Recent studies suggest a <b>specificity</b> of 99.9% and 99.8% respectively.</p>	<b>97.5-100 (n=NR)</b>	<b>99.8-99.9 (n=NR)</b>	<p><b>Phipps et al 2020<sup>56</sup></b></p> <ul style="list-style-type: none"> <li><b>Positive samples tested:</b> Only six patients with samples 14 days post symptom onset, the point at which the highest sensitivity was recorded. 173 suspected COVID-19 cases with 76 were confirmed positive by PCR methods.</li> <li><b>Negative samples tested:</b> Plasma samples from healthy donors (2019 blood donations and 2020 blood donations from healthy donors without recent illness)</li> <li><b>Reference standard:</b> PCR method for suspected COVID-19 cases to confirm positives; for negatives apparent healthy donors</li> </ul>	38 (all days) (n=76) 7 (<3 days) (n=15) 30 (3-7 days) (n=27) 33 (5-15 days) (n=15) <b>83 (after 14 days) (n=6)</b>	<b>100 (n=656)</b>
<p><b>Atruchecks Limited<sup>31</sup></b>  Abbott claim their test is 100% <b>sensitive</b> (88 Samples) and 99.6% <b>specific</b> (1070 Samples).</p>	<b>98.5 (n=132)</b> <b>100</b>	<b>99.5 (n=186)</b> <b>99.6</b>	<p><b>Public Health England (PHE) evaluation of the Abbott antibody test<sup>57</sup></b></p> <ul style="list-style-type: none"> <li><b>Positive samples tested:</b> 96 samples defined by a positive PCR from a swab sample for that patient</li> </ul>	<b>92.7 (all days) (n=96)</b> 93.4 (≥14 days)	<b>100 (n=759)</b>

<p>Our UK Accredited Partner Lab have run their own internal verification of these claims and achieved a <b>sensitivity</b> of 98.5% (132 Samples) and a <b>specificity</b> of 99.5%. (186 Samples).</p>	(n=88)	(n=1070)	<ul style="list-style-type: none"> <li>• <b>Negative samples tested:</b> 759 negative samples were included in the evaluation (351 samples that are rheumatoid factor, CMV, EBV or VZV positive; 11 seasonal coronavirus positive samples and 395 historic samples, 2 samples unclear). These samples have been chosen based on their collection before mid-2019 to ensure they are SARS-CoV-2 antibody negative, but will contain samples containing antibodies to other seasonal coronaviruses to provide an additional screen for the assay</li> <li>• <b>Reference standard:</b> PCR method and pre-COVID-19 samples</li> </ul>	(n=82) 93.9 (≥21 days) (n=76)	
<b>Epitope Diagnostics inc. (EDI) Antibody test (EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit)</b>					
<p><b>Summerfield Healthcare<sup>16</sup></b> We have a trusted product which is <b>specific</b> to COVID-19 and <b>sensitive</b>. As with all of these kits they undergo regular testing to ensure <b>accuracy</b> and <b>reliability</b> which on the last occasion were <b>100% accurate for both positive and negative samples</b>. Antibody test is very specific for COVID-19 (some inferior tests can mistake other infections for COVID-19 and wrongly reassure you); it is also very sensitive for the specific IgG antibody.</p>	NR (n=NR)	NR (n=NR)	<p><b>Manufacturer's clinical performance of test<sup>58</sup></b></p> <ul style="list-style-type: none"> <li>• <b>Positive samples tested:</b> RT-PCR confirmed positive patients.</li> <li>• <b>Negative samples tested:</b> Normal healthy patients with samples collected prior to the COVID-19 outbreak.</li> <li>• <b>Reference standard:</b> PCR method and pre-COVID-19 samples</li> </ul> <p><b>Krüttgen et al 2020<sup>59</sup></b></p> <ul style="list-style-type: none"> <li>• <b>Positive samples tested:</b> The sera of the 31 patients with positive SARS-CoV-2 PCR were collected 11.9 days (±5.0 days) post onset of symptoms. 22 sera were considered SARS-CoV-2 IgG positive (positive on at least two assays).</li> <li>• <b>Negative samples tested:</b> 53 sera were regarded as IgG negative</li> <li>• <b>Reference standard:</b> A serum was regarded as SARS-CoV-2 IgG negative if at least three of the four assays compared here (for the Euroimmun assay, the EDI assay, the Mikrogen assay, and the Viramed assay) had a negative test result applying the manufacturer's interpretation criteria. A serum was regarded as SARS-CoV-2 IgG positive if at least two of the four assays had a positive test result (comparator tests are also part of reference standard).</li> </ul>	98.4 (n=187)	99.8 (n=624)
<b>Randox PCR Antigen test (Randox Covid-19 Home Testing Kit)</b>					
<p><b>Randox<sup>23</sup></b> This is a PCR based test, utilising Randox Biochip Technology, to provide an <b>accurate diagnosis</b> for Covid-19.</p>	NR (n=NR)	NR (n=NR)	<p><b>Manufacturer's clinical performance of test<sup>42</sup></b></p> <ul style="list-style-type: none"> <li>• <b>Positive samples tested:</b> NR</li> <li>• <b>Negative samples tested:</b> NR</li> <li>• <b>Reference standard:</b> NR</li> </ul>	NR (n=NR)	NR (n=NR)

			<p><b>Public Health England (PHE) evaluation of the Randox antigen test<sup>60</sup></b></p> <ul style="list-style-type: none"> <li>• <b>Positive samples tested:</b> None</li> <li>• <b>Negative samples tested:</b> The assessment sample-panel totalled 195 specimens, including upper or lower respiratory clinical specimens negative for SARS-CoV-2 as determined by the validated in-house PHE PCR assay and dilutions of SARS-CoV-2</li> <li>• <b>Reference standard:</b> PHE PCR assay</li> </ul>	<p><b>NR (n=0)</b></p>	<p><b>100 (n=195)</b></p>
<p><b>Primerdesign Ltd Antigen test (Coronavirus (Covid-19) genesig Real-Time PCR assay)</b></p>					
<p><b>Rightangled Healthcare<sup>22</sup></b>                  Studies confirm Primerdesign COVID-19 assays are <b>highly specific</b> for the detection of SARS-CoV-2 virus and detection of coronavirus COVID-19 disease.                  Independent Clinical Performance Evaluation of Primerdesign COVID-19 assay by the National Infection Service, Public Health England, Colindale confirmed the <b>specificity</b> of this assay using upper or lower respiratory clinical samples from patients and known SARS-CoV-2 positive material. PHE confirmed the assay showed &gt;98% specificity to SARS-CoV-2 virus in clinical samples.                  An Independent Clinical Performance Evaluation by an NHS Clinical Pathology Laboratory using patient samples with respiratory symptoms confirmed the assay was 100% <b>specific</b> when tested against known positive and negative SARS-CoV-2 clinical samples.</p>	<p><b>98 (n=50)</b></p>	<p><b>100 (n=50)</b></p>	<p><b>Manufacturer's clinical performance of test<sup>43</sup></b></p> <ul style="list-style-type: none"> <li>• <b>Positive samples tested:</b> Contrived oropharyngeal swabs (50 positive)</li> <li>• <b>Negative samples tested:</b> Contrived oropharyngeal swabs (50 negative)</li> <li>• <b>Reference standard:</b> 50 swabs were contrived with SARS-CoV-2 whole viral genomic RNA</li> </ul> <p><b>van Kasteren et al 2020<sup>61</sup></b></p> <ul style="list-style-type: none"> <li>• <b>Positive samples tested:</b> Clinical samples previously submitted for routine SARS-CoV-2 diagnostics for which the presence of various amounts of SARS-CoV-2 RNA had been confirmed using in-house PCR.</li> <li>• <b>Negative samples tested:</b> Clinical samples with confirmed respiratory viruses (influenza virus type A (n=2), rhinovirus (n=2), RSV-A and -B)</li> <li>• <b>Reference standard:</b> SARS-CoV-2 RNA had been confirmed using in-house PCR</li> </ul> <p><b>Public Health England (PHE) evaluation of Primerdesign antigen test<sup>47</sup></b></p> <ul style="list-style-type: none"> <li>• <b>Positive samples tested:</b> None</li> <li>• <b>Negative samples tested:</b> : The assessment sample-panel totalled 195 specimens, including upper or lower respiratory clinical specimens negative for SARS-CoV-2 as determined by the validated in-house PHE PCR assay and dilutions of SARS-CoV-2</li> <li>• <b>Reference standard:</b> PHE PCR assay</li> </ul>	<p><b>94.7 (1-2x LoD) (n=38)</b></p> <p>100 (3x LoD) (n=7)</p> <p>100 (4-5x LoD) (n=5)</p> <p><b>62.5 (n=16)</b></p> <p><b>NR (n=0)</b></p>	<p><b>100 (n=50)</b></p> <p><b>100 (n=6)</b></p> <p><b>100 (n=195)</b></p>
<p><b>LabCorp Antigen test (COVID-19 RT-PCR test with Pixel by LabCorp™ COVID-19 test home collection kit)</b></p>					
<p><b>LabCorp<sup>35</sup></b>                  Customers provided with link to <b>FDA Emergency Use Authorization Summary</b>.</p>	<p><b>100 (NP swabs) (n=40)</b></p> <p><b>100 (BALs) (n=40)</b></p>	<p><b>100 (NP swabs) (n=50)</b></p> <p><b>100 (BALs) (n=50)</b></p>	<p><b>Manufacturer's clinical performance of test<sup>45</sup></b></p> <ul style="list-style-type: none"> <li>• <b>Positive samples tested:</b> Positive samples were comprised of 40 NP swabs and 40 BALs spiked with quantitated live SARS-CoV-2. 10 samples each were spiked at 8x, 4x, 2x, and 1X LoD.</li> <li>• <b>Negative samples tested:</b> Negative samples include 50 NP swabs and 50 BALs.</li> <li>• <b>Reference standard:</b> Contrived samples</li> </ul>	<p><b>100 (NP swabs) (n=40)</b></p> <p><b>100 (BALs) (n=40)</b></p>	<p><b>100 (NP swabs) (n=50)</b></p> <p><b>100 (BALs) (n=50)</b></p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

<b>Rutgers Clinical Genomics Antigen test (Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay)</b>						
<b>Hims<sup>36</sup></b> Customers provided with link to <b>FDA Emergency Use Authorization Summary.</b>	<b>100 (n=30)</b>	<b>100 (n=30)</b>		<b>Manufacturer's clinical performance of test<sup>44</sup></b> <ul style="list-style-type: none"> <li><b>Positive samples tested:</b> 30 contrived positive samples were tested</li> <li><b>Negative samples tested:</b> 30 contrived negative samples were tested</li> <li><b>Reference standard:</b> Contrived samples</li> </ul>	<b>100 (n=30)</b>	<b>100 (n=30)</b>

For peer review only

**Table 3:** Availability of finger-prick antibody tests post MHRA withdrawal from market notice (websites accessed on 11<sup>th</sup> to 12<sup>th</sup> June 2020)

Website	Status	Comments
PillDoctor <sup>32</sup>	Still available	<i>Test appears to still be available for purchase</i>
YourHealthFirst Clinic <sup>38</sup>	Still available	<i>Test appears to still be available for purchase</i>
Summerfield Healthcare <sup>16</sup>	Not currently available	<b>Webpage suggests finger-prick antibody test still available but not available in subsequent drop down menu.</b>
Doctorcall <sup>15</sup>	Not currently available	"Coming soon"  <b>Option on website to be notified when product is back in stock</b>
WebMed Pharmacy <sup>34</sup>	Not currently available	"Sorry the item you have selected is not currently available, please choose another option"  "Due to the high demand of orders, the Antibodies blood test service is currently not available."
Superdrug <sup>40</sup>	Not currently available	"We have temporarily halted the COVID-19 antibody testing service. If you have any questions please send us a message through your account."
Zava <sup>25</sup>	Out of stock	"This product is temporarily out of stock."  <b>Option on website to be notified when product is back in stock</b>
Better2Know <sup>19</sup>	Out of stock	"Currently out of stock"  <b>Website links to guidance from MHRA.</b>
Antibody Solutions <sup>28</sup>	Out of stock/ Modified test	"Please note: These kits are no longer in stock; however, we are offering a full blood sample collection service, either at your home or at one of our partner clinics."
Blue Horizon Medicals <sup>18</sup>	Modified test	"Ordering this test will allow us to send you a vacutainer kit, which allows a healthcare professional to draw a venous blood sample from your arm. You should only order this kit therefore if you have access to a healthcare professional with the appropriate skills. Phlebotomy should NOT be attempted by those who are unskilled."
Qured <sup>21</sup>	Modified test	"A healthcare professional will visit your home to take a venous blood sample."  "The antibody tests currently used by our laboratory are the Abbott test if you opt for venous blood collection by a healthcare professional, or the Siemens test if you opt to collect your blood sample yourself"  "These tests are currently validated for venous blood draw only, which is why our service includes an at-home blood draw from a healthcare professional. Home self-collection of blood using a finger prick kit for antibody testing has been temporarily paused pending evaluation by the Medicines and Healthcare Products Regulatory Agency (MHRA)."
CityDoc <sup>14</sup>	Modified test	"We are able to offer blood collection by the normal practice of intravenous blood sampling at our clinics across the UK and sent to our accredited UK laboratory for testing."
Atruchecks Limited <sup>31</sup>	Modified test	"PHE approved Abbott test in our accredited lab. Venous sample taken in central London clinic, off Harley street (W1)"
London Medical Laboratory <sup>33</sup>	Modified test	"This option is so you can arrange a home or workplace visit by a phlebotomist to take your blood for you."
The Online Clinic (Online Clinic (UK Limited) <sup>26</sup>	Suspended/ Modified test	"The self-collect home sampling service is currently suspended but will be back shortly. Please check back later."  "The Medicines and Healthcare Regulatory Agency is currently conducting a review of self-collect blood samples for this type of test and the service is unavailable until that review concludes. We now offer a home-sampling service where a phlebotomist attends your home (or other premises) to collect the blood sample from a vein. "
MyHealthcare Clinic <sup>29</sup>	Withdrawn/ Suspended	"We have unfortunately had to withdraw the PHE Approved Antibody Home Testing Kits, per the unexpected Government / MHRA ruling on 26 May re private testing. We do not currently have a date for when these Home Tests will be next available to private patients."
Medichecks <sup>37</sup>	Withdrawn/ Suspended	"Currently, the only way to get a private coronavirus antibody test is to buy a venous blood test where you will need to visit a nurse or health professional to have a sample collected from a vein in your arm. All private laboratories and private testing companies have paused self-collect finger-prick testing while the MHRA conducts its review. However, we are confident that this service will resume shortly once the laboratories

		have completed their validation studies.”
Babylon <sup>39</sup>	Withdrawn/ Suspended	<p>“Important update on COVID-19 Antibody Tests. The MHRA (the government regulator responsible for medicines and medical devices) has asked that all COVID-19 antibody testing from finger-prick blood samples be paused. The MHRA decision has impacted all testing of this type nationwide.”</p> <p>“The lab will not be offering further testing services until the MHRA have provided clearance to do so.”</p>

For peer review only

1  
2  
3 **Figure 1.** Proportion of home-sampling COVID-19 tests identified which met/did not meet each of  
4 the predefined criteria for clear communication.  
5

6 **Figure 2.** Recommendations given by websites on when to take the molecular virus tests and  
7 antibody tests. Test accuracy is dependent on correct timing.  
8  
9

### 10 **Author contributions**

11 STP, SB, AJS, KF, MJP, CD, JG, IMH, OO, MS, JJD contributed to the conception of the work and  
12 interpretation of the findings. OO and JG performed the Google searches. STP, SB, KF, JG, OO, IMH,  
13 and MJP extracted the data. STP, AJS, MJP and CD undertook the analysis and drafted the  
14 manuscript. STP, SB, AJS, KF, MJP, CD, JG, IMH, OO, MS, JJD critically revised the manuscript and  
15 approved the final version. STP acts as guarantor. The corresponding author attests that all listed  
16 authors meet authorship criteria and that no others meeting the criteria have been omitted.  
17  
18  
19  
20  
21  
22

### 23 **Funding statement**

24 This paper presents independent research supported by the NIHR Birmingham Biomedical Research  
25 Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of  
26 Birmingham. Dr Taylor-Phillips is supported by an NIHR Career Development Fellowship (CDF-2016-  
27 09-018). MS is supported by the National Institute for Health Research (NIHR) Applied Research  
28 Collaboration (ARC) West Midlands. The views expressed are those of the author(s) and not  
29 necessarily those of the NHS, the NIHR or the Department of Health and Social Care.  
30  
31  
32  
33  
34  
35  
36  
37

### 38 **Competing interests disclosed**

39 We have read and understood BMJ policy on declaration of interests and declare the following  
40 interests: STP is funded by the NIHR through a career development fellowship; KF is funded by the  
41 NIHR through a doctoral research fellowship; MS reports grants from NIHR Applied Research  
42 Collaboration WM; AJS, SB, MP, CD and JD report funding and support from NIHR Birmingham  
43 Biomedical Research Centre.  
44  
45  
46  
47  
48  
49

### 50 **Acknowledgement**

### 51 **License for publication**

52 I, Sian Taylor-Phillips, the Corresponding Author have the right to grant on behalf of all authors and  
53 do grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in  
54 perpetuity, in all forms, formats and media (whether known now or created in the future), to i)  
55 publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into  
56  
57  
58  
59  
60



1  
2  
3 other languages, create adaptations, reprints, include within collections and create summaries,  
4 extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the  
5 Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links  
6 from the Contribution to third party material where-ever it may be located; and, vi) licence any third  
7 party to do any or all of the above.  
8  
9  
10  
11  
12

### 13 **Ethical approval**


14 Ethical approval not required  
15  
16  
17

### 18 **Data sharing statement**

19 No additional data available  
20  
21  
22


### 23 **Transparency**

24 The lead authors and manuscript's guarantor affirms that the manuscript is an honest, accurate and  
25 transparent account of the study being reported; that no important aspects of the study have been  
26 omitted; and that any discrepancies from the study as planned have been explained.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



195x112mm (120 x 120 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



203x114mm (144 x 144 DPI)

**Supplementary Table 1: Characteristics of included websites and COVID-19 tests**


Name of company	Type of company	Type of test	Name of test manufacturer	Home testing or home sampling	Regulatory approval CE/EUA or *endorsement
Superdrug <sup>40</sup>	Pharmacy	Antibody	Not Reported	Home sampling	-
CityDoc <sup>14</sup>	Private health clinic	Antibody	Not Reported	Home sampling	-
		Molecular	Not Reported	Home sampling	-
Rightangled Healthcare <sup>22</sup>	Online testing specialist	Molecular	Primerdesign Ltd	Home sampling	-
Randox <sup>23</sup>	Laboratory	Molecular	Randox PCR test	Home sampling	-
Samedaydoctor <sup>24</sup>	Private health clinic	Molecular	Not Reported	Home sampling	-
Zava <sup>25</sup>	Private health clinic	Antibody	Not Reported	Home sampling	CE
		Molecular	Not Reported	Home sampling	CE
The Online Clinic (Online Clinic (UK) Limited) <sup>26</sup>	Private health clinic	Antibody	Abbott Laboratories and Roche	Home sampling	-
		Molecular	Not Reported	Home sampling	CE
Doctorcall of Harley Street <sup>15</sup>	Private health clinic	Antibody	Not Reported	Home sampling	CE Endorse UK Government
		Molecular	Not Reported	Home sampling	CE
The Family Planning Association (FPA) <sup>27</sup>	Online sexual health specialist	Molecular	Not Reported	Home sampling	-
YourHealthFirst Clinic: Harley Street <sup>38</sup>	Private health clinic	Antibody	Not Reported	Home testing	CE
Antibody Solutions <sup>28</sup>	Company specialising in beauty treatments	Antibody	Not Reported	Home sampling	-
		Molecular	Not Reported	Home sampling	Endorse PHE, NHS
MyHealthcare Clinic <sup>29</sup>	Private health clinic	Antibody	Abbott	Home sampling	Endorse PHE
		Molecular	Not Reported	Home sampling	-
MedExpress <sup>30</sup>	Pharmacy	Molecular	Not Reported	Home sampling	-
Summerfield Healthcare <sup>16</sup>	Private health clinic	Antibody	Epitope Diagnostics inc (EDI)	Home sampling	-
		Molecular	Not Reported	Home sampling	-
Atruchecks Limited <sup>31</sup>	Online test supplier	Antibody	Abbott	Home sampling	Endorse PHE
		Molecular	Not Reported	Home sampling	-
PillDoctor <sup>32</sup>	Pharmacy	Antibody	Not Reported	Home sampling	-
	Pharmacy	Molecular	Not Reported	Home sampling	Endorse UK Government
London Medical Laboratory <sup>33</sup>	Laboratory	Antibody	Abbott	Home sampling	CE Endorse PHE
		Molecular	Not Reported	Home sampling	CE Endorse PHE
WebMed Pharmacy <sup>34</sup>	Pharmacy	Antibody	Not Reported	Home sampling	CE Endorse PHE
		Molecular	Not Reported	Home sampling	Endorse PHE

Name of company	Type of company	Type of test	Name of test manufacturer	Home testing or home sampling	Regulatory approval CE/EUA or *endorsement
Babylon <sup>39</sup>	Private health clinic	Antibody	Not Reported	Home sampling	-
Medichecks <sup>37</sup>	Online test specialist	Antibody	Not Reported	Home sampling	CE
LondonDoctorsClinic <sup>17</sup>	Private health clinic	Molecular	Not Reported	Home sampling	Endorse PHE, NHS, UK Government
Blue Horizon Medicals <sup>18</sup>	Online test specialists	Antibody	Not Reported	Home sampling	Endorse PHE
		Molecular	Not Reported	Home sampling	-
better2know <sup>19</sup>	Online sexual health specialist	Antibody	Not Reported	Home sampling	CE
		Molecular	Not Reported	Home sampling	-
Private Harley Street Clinic <sup>20</sup>	Private health clinic	Molecular	Not Reported	Home sampling	Endorse PHE
Qured <sup>21</sup>	Private health clinic	Antibody	Not Reported	Home sampling	CE Endorse PHE
		Molecular	Not Reported	Home sampling	CE
LabCorp <sup>35</sup>	Laboratory	Molecular	LabCorp (139900)	Home sampling	EUA
Hims Inc <sup>36</sup>	Private health clinic	Molecular	Rutgers Clinical Genomics Laboratory	Home sampling	EUA

\* Statement that the test is 'used by', 'approved by' or 'compliant with'.

Abbreviations: PHE, Public Health England; EUA, Emergency Use Authorisation

**Supplementary Figure 1: Reported test manufacturer for the 41 tests for sale included in the cohort.**



\*7 of 13 'Not reported' antibody tests stated it was a finger prick test with no further detail.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4
Bias	9	Describe any efforts to address potential sources of bias	4
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	N/A
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	N/A
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	5
		(b) Give reasons for non-participation at each stage	n/a
		(c) Consider use of a flow diagram	N/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	5
		(b) Indicate number of participants with missing data for each variable of interest	5
Outcome data	15*	Report numbers of outcome events or summary measures	5-8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make	n/a



		clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	7
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	n/a
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	7
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	7,8
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	8
Generalisability	21	Discuss the generalisability (external validity) of the study results	8
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Funding statement

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).